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Human Immunodeficiency Virus (HIV) has impacted the lives of nearly 76 
million and about a million people become infected each year even with the use 
of current preventative strategies and antiretroviral therapy (ART). An ART-free 
remission/cure strategy is needed.  
The HIV-1 reservoir poses a major hurdle to developing an HIV cure as it fosters 
HIV-1 persistence through viral quiescence. Measuring the true size of the 
reservoir is complex owing to dominance of defective HIV-1 proviruses, making 
it harder to specifically target therapies towards the intact proviral reservoir. The 
assays that are currently used under-or over-estimate the size of the reservoir. 
A recently established PCR assay, Intact proviral DNA assay (IPDA) was found 
to differentiate between intact and defective HIV-1 proviruses. It has helped in 
studying the reservoir in adults, but no extensive study using the IPDA have 
been performed in children. 
Objective: To apply the IPDA to study the dynamics of the HIV-1 proviral 
reservoir in children and inform strategies for ART-free remission.  
Methods: IPDA was optimized for use on the limited number of cells that are 
generally available from children, by determining the best type of control 
sample, the optimal DNA isolation technique and genomic DNA input amount 
to analyze each sample. The IPDA was applied to study the composition and 
the dynamics of the different DNA species in the HIV-1 reservoir in participants 
from a previously well characterized cohort (PHACS-AMP) in whom a 




conventional total HIV-1 DNA assay had been used to quantify HIV-1 
reservoirs.   
Results: 25 PHACS-AMP participants were eligible for this study. The 
distribution of intact HIV-1 proviruses/million PBMCs was lower in those that 
achieved virologic suppression at <1 year of age compared to those that 
achieved virologic suppression (VS) between 1-5 years of age. In contrast the 
defective HIV- 1 proviruses demonstrated an expansion in size regardless of 
age at VS. 
Conclusion: Early effective ART decreases the size of the reservoir in children 
with perinatal HIV-1 infection which is mainly due to the decline in the intact 
HIV-1 proviral reservoir.  
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History of HIV-1 
The human immunodeficiency virus type 1 (HIV-1) is a retrovirus belonging to 
the family of lentiviruses that has a diploid single stranded RNA genome. In 
1981, Acquired Immunodeficiency Syndrome (AIDS), a new disease prevalent 
amongst men who have sex with men (MSM), blood transfusion recipients and 
injection drug users was discovered1,2. AIDS was detected in children around 
19823. With AIDS, the immune system of the patient is compromised to the 
point that opportunistic infections that are not usually harmful, become deadly. 
After much research and collaboration, HIV-1 (then called HTLV-III) was 
discovered to be the causative agent of AIDS in 19831,4,5. Later, in 1986, a 
similar virus causing immunological symptoms in people in West Africa was 
discovered and termed HIV-2. It was found that without treatment, HIV-1 has 
higher mortality rates than HIV-26. The life expectancy, without treatment, for 
children with HIV-1 was about 2-3 years while adults lived on for a median of 
about 8-10 years after infection7,8. The modes of transmission of HIV-1 in adults 
are through sexual contact, sharing needles and blood transfusions1,4,5,9.  In 
infants, the virus can enter infant cells in-utero, during the delivery, or after birth 
with breastfeeding10,11. Since the discovery of HIV-1, extensive studies have 
been performed to combat the HIV/AIDS epidemic and prolong lives with 
antiretroviral treatment (ART)12-19.  
HIV-1 has affected the lives of nearly 76 million people since the start of the 
epidemic.  




Even with the current preventative strategies and antiretroviral therapies, 
(ART), nearly 1.7 million people were newly infected in 2019 of which about 
150,000 were children20. HIV-1 continues to pose a public health problem 
especially in the pediatric population where measures have been taken to 
diminish mother to child transmission3,11,21. ART is a lifelong regimen which 
needs to be strictly adhered to, for it to be effective. However, it is not easy to 
adhere to it strictly especially for the pediatric population. Therefore, the field 
has moved towards finding a cure or ART-free remission for HIV-1. Clearly, 
ART is not enough to provide a cure therefore extensive studies are ongoing to 
follow through on this agenda22-24.  
 
HIV-1 Biology & Pediatric HIV-1 Infection 
Biology: HIV is a lentivirus belonging to the family Retroviridae. It has a diploid 
positive strand RNA genome which is 9 kilobases in length. HIV is of two types: 
HIV-1 and HIV-2. It is a zoonotic disease that originated from cross-species 
transmission from chimpanzees to humans. HIV-1 is found all across the world 
and has several clades which are distributed amongst 4 groups: M (main), O, 
N (non-M and Non-O) and P. HIV-1 group M is the most common and has nine 
subtypes: A, B, C, D, F, G, H, J & K. It also has 49 circulating recombinant forms 
(CRFs). Of the nine subtypes, subtype B viruses are most commonly found in 
Europe, Australia, and North America. All the subtypes of group M can be found 
in Africa. However, subtype C viruses are common worldwide while clade A 
viruses circulate mainly in Eastern and Central African countries.  




As for the other groups of HIV-1, group O has been isolated from patients in 
Cameroon, Equatorial Guinea, and Gabon, while group N and P have been 
isolated from patients in Cameroon as well.   
These different subtypes/clades of HIV-1 could have arisen as a result of error-
prone RNA polymerase activity or genetic recombination as part of reverse 
transcription of the HIV-1 genome6,25.   
HIV-1 has an affinity for infecting cells that express CD4. T cells and some 
monocyte-derived macrophages (MDM) express CD4 as a cell surface 
receptor. Therefore, HIV is characterized by its tropism for T cells and MDMs 
as T-Cell tropic and M-tropic respectively. Viruses that infect both T cells and 
MDMs have also been observed and are termed as dual tropic. For successful 
entry, HIV usually uses a co-receptor, CCR5 (R5 virus) or CXCR4 (X4 virus), 
adding another level of tropism for the virus6,26.  
The core of HIV-1, i.e., nucleocapsid, genome and capsid, is cone shaped and 
cylindrical (Figure 1 A). The 9 kilobase genome encodes several genes and 
has 10 open reading frames (ORFs). Of the 10 open reading frames, only 3 
genes are common across all retroviruses: gag, env and pol. The gag and env 
genes encode structural proteins while the pol gene encodes enzymes that are 
important for viral replication. The remaining genes Vif, Vpr, Tat, Rev, Vpu, and 
Nef are accessory and have several essential functions in the viral lifecycle6,25.  
The gag and pol genes are translated as a polyprotein and are separated by a 
single frameshift giving rise to 2 ORFs.  




The env gene encodes a protein product, which when cleaved using cellular 
proteases forms two components: gp120 which forms the main spike protein of 
HIV-1 and the transmembrane region gp41 which acts as the fusion peptide for 
membrane fusion during entry. The gag protein consists of the matrix, capsid, 
late domain (p6, p1, p2) and nucleocapsid proteins.  
Within the matrix (MA) protein domain the plasma membrane targeting, 
membrane binding regions and the nuclear localization signal that allows the 
viral genome to enter the nucleus can be found. The capsid (C) domain has 
gag-binding regions which allow gag to multimerize, and the nucleocapsid (NC) 
domain has zinc finger regions that allow RNA binding to take place through 
interaction of the four RNA stem loops that make up the core packaging signal, 
psi (ψ). The late domain has proteins like p6 which are required for budding. 
The Pol protein contains the enzymes protease, reverse transcriptase, and 
integrase which are essential for viral infectivity. The viral protease is important 
for cleaving gag and gag-pol into their components. Reverse transcriptase 
transcribes the  RNA viral genome to viral cDNA, and integrase inserts this 
cDNA into the host genome. The 5’ untranslated region of the viral RNA 
genome has several secondary structures that can mediate elongation, splicing 
of the viral transcripts, reverse transcription, packaging and dimerization of viral 
genome. There are certain regions in this 5’ UTR where the t-RNA primer 
needed for reverse transcription can bind and be packaged into the virion 
(mediated by the NC domain).  
  




HIV-1 Lifecycle: The virus enters the human host through several routes 
including but not limited to sexual contact or blood transfusions. In infants, the 
virus can enter cells in-utero, during delivery, or after birth with breastfeeding. 
The virus then binds to the CD4 receptor on the T cells or monocyte-derived 
macrophage (MDM) using the gp120 of the env protein which leads to a 
conformational change. This change allows the gp120 to bind to a co-receptor, 
usually either CCR5 or CXCR4, leading to another conformational change. The 
second conformational change allows the gp41 to be exposed and for fusion to 
occur at the plasma membrane.  
Until recently (Figure 1B), it was believed that once fusion occurred, the viral 
core would disassemble soon after and the viral pre-integration complex (viral 
cDNA, integrase, vpr, gag MA p17) would then enter the nucleus and facilitate 
integration of the viral DNA6,25,26. However, it was recently discovered that the 
viral core remains intact even after fusion and enters the nuclear envelope 
followed by traversing the nuclear pore complex into the nucleus27. Within the 
intact core, the virus’s reverse transcriptase (RT) binds to the HIV-1 RNA and 
converts it into cDNA (Figure 1B). It has been proposed that the dNTPs for RT 
enter the core though pores in the capsid27,28. Reverse transcription begins 
when the t-RNA primer binds to the Ru5 region of the HIV-1 RNA template and 
starts transcribing the RNA to DNA and then stops. The RT then jumps to the 
u3R region of the template RNA and begins transcribing it to DNA. During this 
jump, the RT may latch onto the other copy of RNA if it comes across a break 
or nick in the template strand or if there is more than one virus infecting the 
same cell (quite rare)29.  




As the reverse transcription proceeds the viral RNA is degraded by the RNAse 
activity of RT, except RNA near the u3R region which acts as a primer for 
positive strand synthesis.  
Once reverse transcription is complete, the RU5U3R portion of the cDNA 
molecule is present in duplicate and forms what is known as the long-terminal 
repeat (LTR). LTRs are important for the integration of viral cDNA into the host 
genome. After recognizing certain sequences within the 2LTR region, the 
enzyme integrase is then able to co-linearly insert the HIV-1 DNA into the host 
genome. This leads to the formation of the proviral reservoir in cells.  
The HIV DNA can get inserted into transcriptionally active or inactive genes, 
and in the opposite orientation to the human gene.  
This integrated DNA can then be transcribed to form spliced or unspliced 
mRNA. After the virus has generated mRNA (multiply spliced), it transcribes the 
viral mRNA using the host cell ribosomes into viral proteins using the accessory 
proteins tat and rev. As the cycle moves towards the later stages, more 
unspliced (full-length genome) or single spliced mRNAs are generated. The 
unspliced mRNAs are then packaged to form new virion particles. Packing 
occurs when sequences in the packaging region of the genome generate a 
kissing loop that allows the two RNA strands to bind to one another non-
covalently at the 5’ ends. Individual gag monomers using the Zn finger 
associate with the other secondary structures in the packaging region of the 
viral RNA genome. This allows the specific interaction of gag nucleocapsid (NC) 
with the viral RNA; gag then multimerizes to form a higher-level structure, which 
is preferred for packaging. With the help of the late domain, p6, the gag binds 




to host ESCRT proteins that are needed for assembly and budding. The gag 
matrix domain allows it to be targeted to the lipid-rich regions of the plasma 
membrane where the HIV-1 env proteins are also present. As gag binds to the 
lipid-rich regions, it also multimerizes, leading to lipid concentration in one area, 
and through complex mechanisms involving the ESCRT host proteins the virion 
buds out of the cell. Once the virus has budded, the host cell proteins packaged 
into the virus cleave the gag MA region to form a stable mature structure6,25,26. 
Pediatric HIV-1 Infection: Nearly 150,000 children were newly infected with HIV 
in 201920. HIV-1 can be transmitted from a positive mother to her child in three 
ways: in-utero, intra-partum, or post-partum through breast feeding8,10. The 
neonate is said to be infected in-utero if two independent blood samples taken 
within 48 hours of birth show positive results for HIV-1 DNA or RNA. A neonate 
is said to be infected perinatally (intra-partum or post-partum) if samples of 
blood taken within a week of birth are negative but 2 or more subsequent 
samples obtained from blood drawn on different visits are positive for HIV-1 
DNA.8,10,11  
If the infection is transmitted in-utero, the infection progresses more rapidly than 
if it is transmitted at the other two times. The reasons stated for more rapid 
progression of the infection are the immunology of the neonate and ability to 
treat sooner with respect to timing of infection especially in cases of peri-partum 
infections8,30 
  










Figure 1. HIV-1 & HIV-1 Lifecycle 
A: The HIV-1 virion conical core (NC, RNA and CA) is encased by the matrix 
followed by a lipid bilayer. The spike protein on the surface gp120 is embedded in 
the bilayer and is used for attachment to the cell6, 26. B. The life cycle of HIV-1 
follows the steps of attachment, fusion27, uncoating of the core in the nucleus vs 
the original belief of uncoating right after fusion, reverse transcription, integration, 
viral protein generation, assembly, and release of the virion6, 25, 26. 
Figures created with Bio-render.com. 
 




The immunologic environment of the fetus in-utero is tolerogenic owing to 
exposure to maternal antigens through the placenta30. The inflammatory 
responses are controlled by high levels of transforming growth factor-beta 
(TGF-β). TGF-β pushes the naïve CD4 T cells into a CD4 Treg lineage31. In 
addition, innate immune cells respond to TLR stimulants with the release of 
cytokines that push the differentiation of naïve CD4 T cells in the direction of 
CD4 Th17 cells and Th2 cells rather than Th1 cells. This gives rise to a 
predominantly anti-inflammatory environment30,32-34.  
In the case of HIV-1 infection, this tolerogenic environment can interfere with 
the HIV-1 latency. The immune repertoire circulating in the blood of neonates 
is dominated by naïve CD4 T cells (low to no expression of CCR5) while the 
intestinal epithelium consists of a large proportion of CD4 T cells expressing 
CCR535,36. Some of these intestinal T cells are CD4+ CCR5+ CCR6+ T cells 
(Th17) and are highly permissive for infection by HIV-1.37,38 These Th17 cells 
then decline in number and could leave the patient vulnerable to immune 
activation as a result of infection by extracellular pathogens or commensals30. 
Immune activation can be caused by response to vaccines, mixed feeding 
(breast and other forms of feeding the neonate), changes in the microbiota as 
the neonate grows. Increased immune activation leads to increased HIV 
replication, paving the way for the formation of a reservoir of HIV-1. Thus, the 
tolerogenic environment of the neonate can change based on multiple factors 
paving the way for a more robust infection by HIV-1 30.  
 
  





In 1980s, a drug used in cancer treatment, was found to be capable of inhibiting 
reverse transcriptase, a direct acting dideoxynucleoside reverse transcriptase 
inhibitor (NRTIs), azidothymidine (AZT) and was used for treating HIV-1 
infections39. It was after this step that different categories of inhibitors were 
developed to be combined to bring virus replication under control: non-
nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors, entry 
and attachment inhibitors and integrase inhibitors. In the late 1990s, 
combination antiretroviral therapy (now called ART) to potently suppress virus 
was replication was identified18,40-47. Over the past two decades, these new 
drugs when combined gave rise to highly active antiretroviral therapy (now 
called ART), improved the outcomes for HIV-1/AIDS in terms of life expectancy 
and reduced the count of tablets taken per day to 1-3. The transmission of HIV-
1 from a HIV positive mother to her child also is reduced with the use of effective 
ART3,21.  
ART has given people living with HIV and AIDS (PLWHA) benefits such as 
increased life span and better quality of life, but a patient has to adhere to it 
strictly for it to be effective in keeping the plasma viral load at undetectable 
levels and to prevent the selection of drug-resistant strains of HIV-1. Strict 
adherence to ART is not easy and even with effective ART, the virus cannot be 
fully eliminated48-52. Treatment interruptions give rise to viraemia which is a 
consequence of the reservoir of HIV-112,53. Even with the field moving towards 
early effective ART given at the time of diagnosis of HIV-1 infection, the 
reservoir still persists, albeit smaller compared to when ART is initiated during 




chronic infection54-62. Hence, there is a need to develop new lines of treatment 
that can specifically target the reservoir so that people living with HIV/AIDS 
(PLWHA) can be taken off treatment without rebound of viremia for long periods 
of time13.   
 
Definitions 
Early effective/suppressive ART: Early effective ART refers to the 
administration of ART within 3 months of infection, and the achievement of 
control of viremia in a few weeks post initiation of ART55,63.  
Virologic suppression: Control of viremia such that the plasma viral load (pVL) 
≤400 copies/mL for the duration of the study while permitting single 
measurements of pVL≥400 copies/mL in between measurement of pVL≤400 
copies/mL59,60. 
HIV-1 provirus: HIV-1 DNA that is integrated into the genome of an infected 
cell6,64. 
Viral replication: A process in which virus production leads to infection of new 
cells (previously not infected), which then produce infectious virus that can 
infect more non-infected cells23.  
Replication-competent HIV-1 provirus: HIV-1 provirus that is capable of 
producing and releasing virions that can cause productive infection of cells23,64-
68. 
 




Intact HIV-1 proviral genomes: HIV-1 genomes lacking fatal small and large 
deletions, insertions, premature stop codons or hypermutations 64,65,69. 
Defective HIV-1 proviral genomes: HIV-1 genomes which are not capable of 
producing infectious viruses. Defective proviruses contain large deletions, 
spanning one or more regions of the genome, insertions, frameshift mutations, 
hypermutations mediated by APOBEC3G/F, and mutations that affect viral 
fitness 69-73. 
Latency: A reversible state in which cells with integrated HIV-1 genomes do not 
produce virions and expression of viral proteins is limited or absent 
(transcriptionally silent)23,49,64-68,74.  
Cure: There are several definitions of cure in HIV-1 infection.  
Sterilizing cure: Eradication of all forms of replication-competent virus23,65,75. 
Functional cure: Sustaining virologic suppression (control of viral replication) 
without antiretroviral therapy23,65,75.  
ART-free Remission: In the context of perinatal infection, remission is defined 
as the ability to sustain virologic suppression in the absence of ART, while 
maintaining normal CD4 levels and immune responses to childhood vaccines76. 
Reservoir: Population of cells or anatomical sites that allow the persistence of 
replication-competent proviruses for several years even in patients on effective 
ART. Reservoirs are relatively stable as they are protected from ART or the 
immune system compared to actively replicating virus. Currently, the reservoir 
is thought to be found mostly in resting CD4 T cells77,78.  




Resting CD4 T cells can get activated upon presence of stimulus, become 
effector cells permissive of viral production and gene expression (short-lived) 
and then revert to the resting phenotype wherein they become long-lived cells 
again66. There is increasing evidence that other cell types can also act as 
reservoirs79,80. For example, macrophages, which are relatively long-lived once 
infected,81-83 and other compartments in the body like the CNS,84,85 can act as 
reservoirs, however further studies are needed to confirm this with respect to 
longevity of the cells/tissues 23,66,68. 
Latent reservoir :  A population of quiescent cells that harbor HIV-1 proviruses 
that are replication-competent but do not express viral proteins or produce 
virions while the cells are quiescent. The latent reservoir is not affected by the 
immune system or ART23,64-66,68,86.  
Active reservoir: Transcriptionally active cells that harbor HIV-1 proviruses 
capable of producing HIV-1 RNA and proteins, found in persons on effective 
ART64,68 
Inducible HIV-1 provirus: Integrated HIV-1 DNA in infected cells which can be 
stimulated by antigens or activating agents to produce replication-competent 
virus and express viral proteins. 23,49,64-68 
 
Cure/Long-term ART-free Remission 
After the discovery of HIV as the cause for the fatal disease AIDS, there was 
an urgent need for therapies1,4,5. This need was met with the development of 
ART beginning with repurposing AZT from cancer treatment to HIV-1 treatment. 




Later, combination antiretroviral therapy was developed by using two or more 
drugs to control the viral lifecycle and suppress viral replication to a point where 
viremia was below the detection limit of clinical assays13-16,39,42,43,45-47. Although 
effective ART was able to arrest viral replication and control viremia, it was 
unable to cure HIV-1 infection as evidenced by the rebound of viremia within 2-
4 weeks of ART interruption (ATI)53,87. The reason for this rebound was found 
to be replication-competent integrated HIV-1 DNA in quiescent long-lived 
memory CD4 T cells (latent reservoir). 48,49,52,77,88. This latent reservoir poses a 
barrier to cure as it can be reactivated89. The latent reservoir is persistent and 
has limited to no expression of viral proteins while the cells are in a resting 
state. Owing to this, cells in the latent reservoir cannot be differentiated from 
non-infected cells and therefore are not subject to immune responses89.  
Studies on people infected with HIV, who were on effective ART for 7 years 
showed that the latent reservoir decays slowly with a half-life of 44 months 
which indicates that a person would have to stay on effective ART for at least 
73.4 years to fully eradicate one million latently infected cells50,51,90,91. Even 
when ART is initiated early, that is during acute HIV-1 infection, upon cessation 
of ART viral rebound is observed53,92-94. In addition, ART is not easily accessible 
to everyone, adherence to the regimen can be difficult, and ART has toxicity 
associated with long-term use95,96. In spite of current preventative and 
treatment strategies, at least 1.7 million new infections of HIV-1 occur 
worldwide annually 20,97. The issues with ART have led to the search for a cure 
for HIV-1 infection beyond using ART96,98.  
 




Seeding and maintenance of the reservoir 
Naïve T cells do not express high levels of cell surface receptors. When the 
naïve T cell is exposed to an antigen-presenting cell carrying a cognate antigen, 
cell surface receptors like CD4, CCR5, CD28 etc. are upregulated on the T cell 
to assist in antigen recognition and elicit an appropriate immune response. 
When a person is infected with HIV-1, the expression of high levels of cell 
surface receptors (CD4, CCR5/CXCR4) allows the virus to enter the cell. The 
activated T cells are also transcriptionally active, permitting viral infection. This 
favorable environment permits the HIV-1 virus to infect activated T cells i.e., 
memory T cells that are activated in response to a cognate antigen. At the end 
of an immune response, the majority of the activated T cell repertoire is cleared 
but a small fraction transitions into resting memory T cells which are long-lived 
and allow the virus to persist99. However, the average half-life of memory T 
cells, is approximately 5.5 months, which is shorter than that of the HIV-1 
reservoir (44 months)50,100-102. Therefore, there must be mechanisms in place 
that help maintain the reservoir in patients after years on effective ART.   
Three such mechanisms have been identified: homeostatic proliferation, 
antigen driven proliferation, and integration into/in close proximity to genes 
involved in cell growth. These mechanisms collectively fall under the term clonal 
expansion96,98,103. Homeostatic proliferation is a part of natural T cell 
homeostasis and occurs when the T cells are exposed to cytokines like 
interleukin (IL)-7 and IL-15104-106. Homeostatic proliferation can lead to increase 
in cell numbers without expression of the HIV-1 genome, thereby protecting the 
infected cell from the immune response107.  




Antigen driven proliferation occurs through repeated exposure to cognate 
antigens108. It is possible that this type of proliferation may lead to expression 
of HIV-1103. 
HIV-1 tends to integrate into active genes109,110. Sometimes these integration  
sites include genes which are associated with cell growth, and can lead to cell 
proliferation, thereby contributing to the maintenance of the reservoir111,112.   
It was observed that majority of HIV-1 clones were from cells harboring 
defective proviruses113. Recently, it was shown that even cells harboring intact, 
replication-competent proviruses can expand clonally114-117.  
Latency 
There are several mechanisms by which HIV-1 maintains its latency. Studies 
have found the following mechanisms to play a role in the maintenance of HIV-
1 latency66,67,96,118: 
• Repressive chromatin states: including but not limited to posttranslational 
modifications(histone + non-histone proteins)119-122 and DNA methylation123. 
• Preference for sites of integration: HIV-1 prefers to integrate into inter-genic 
regions of the active genes, where epigenetic silencing may play a role in 
the maintenance of latency in cells.96,109,110 
• Low levels of host transcription factors: Low levels of host transcription 
factors such as NF-kB, NFAT, AP-1 and low levels of viral protein tat can 
interfere with viral protein production79,124-127. 
• Repressive genetic components: Nucleosomes present in the 5’LTR region 
of the viral DNA can block viral transcription128. In addition, low levels of HIV-




1 tat and another host factor P-TEFb can interfere with the elongation of 
transcripts leading to formation of truncated proteins129.  
• Orientation of the integrated HIV-1 DNA with respect to the host genome: if 
the viral genome is integrated in the opposite orientation to that of the host 
genome, the RNA pol II complexes could collide leading to RNAi, and 
reduction of RNA transcripts of the host and virus. Alternatively, if the 
genome is integrated in the same orientation as that of the host, the RNA 
pol II upstream of the viral genome could disrupt the positioning of the 
factors required for viral transcription present at the 5’LTR promotor site130-
132.  
Strategies for cure/long-term ART-free remission 
Several strategies for cure/remission are under study. These include: latency 
reversal agents which involves the use of mitogens to activate latently infected 
T cells such that they express HIV-1 and can be eliminated (shock and kill)133-
138; latency silencing agents (block and lock)139-141; the use of broadly 
neutralizing antibodies to target viral surface proteins on latently infected cells 
after latency reversal followed by elimination of the infected cell142,143 and 
others. The aim of these strategies is to reduce the size of the replication-
competent reservoir which poses a barrier to cure96,98. To determine if any of 
these strategies are working especially in the setting of a clinical trial, a simple, 
efficient, cost-effective, high-throughput assay is required to study the reservoir 
with respect to intact proviruses. The Intact Proviral DNA assay (IPDA) can 
study the intact proviruses and determine the decay rate of intact proviruses, 
thereby proving to be a helpful assay in cure strategies. It is also requires very 




few cells and can be used to study several types of tissues and 
cells64,65,69,144,145.  
 
Measuring the reservoir 
To find a cure, whether functional or sterilizing, it is important to measure the 
size of the reservoir accurately to observe the effects of the therapies/strategies 
on it and note whether the strategies are effective in eliminating the reservoir 
(sterilizing cure) or the replication competent proviruses (functional cure). To 
achieve this, the method used to measure the reservoir should satisfy a few 
criteria: The assay/method should ideally measure only the replication-
competent proviruses. The assay should be able to work across different 
subtypes, and mutations should not drastically impact the observed results. It 
should be sensitive and specific to not deliver false negatives. Ideally, it should 
not require large specimen volumes or samples65,68.   
➢ Assays that measure the concentration of intact or replication-competent 
proviruses 
➢ Culture-based: 
Quantitative Viral Outgrowth Assay 
The quantitative viral outgrowth assay (QVOA) also known as viral outgrowth 
assay (VOA), was the first assay used to identify the reservoir in HIV-1 
infections74,77,146. It is currently considered the gold standard for measuring the 
reservoir23. The principle of QVOA is based on viral gene expression and state 
of activation of the cell. 










Figure 2. Formation and composition of the HIV-1 reservoir  
A: The proviral reservoir is formed by conversion of viral RNA to viral cDNA within 
the pre-integration complex followed by insertion of the viral cDNA into the host 
genome and survive in a long-lived quiescent CD4+ T cells  
B: The proviral reservoir is complex and consists of different species of HIV-1 DNA 
represented here as different colored circles which are measured using the 
different assays summarized below96,144. On the left side of the figure, are the 
different HIV-1 DNA species that constitute the reservoir and on the right are 
current assays that are used to measure the different DNA species in the 
reservoir23, 64, 65, 68, 69, 73, 77, 90, 96, 116, 144, 145, 148, 151, 155, 178.  
Figures created with BioRender.com. 
 




In the QVOA, purified CD4 T cells from blood or leukapheresis products of 
people infected with HIV-1 are mixed with stimulants such as mitogens (phyto-
hemagglutinin, histone deacetylase inhibitors, anti-CD3/anti-CD28 antibodies, 
irradiated PBMCs depleted of CD8 cells147) in a limiting dilution to push the 
integrated provirus out of latency and promote HIV-1 gene expression. To this, 
activated CD4 T cells from HIV-1-negative donors are added for viral outgrowth. 
A capsid antigen, p24, which is detected in the supernatant of the culture with 
ELISA, is used to measure viral outgrowth. Using Poisson’s distribution, the 
infectious units per million (IUPM) CD4 T cells can be calculated (only possible 
if limiting dilution is used) 23,52,68,74,144,148-151.  
The QVOA has been able to detect 0.03 to 3 replication-competent proviruses 
per million resting CD4 T cells50,148. Earlier CD4 lymphoblasts from HIV-1 
seronegative individuals were used as target or indicator cells; now, cells lines 
or PBMCs can be used152. The QVOA can detect single infected cells, does not 
detect defective proviruses and is a reproducible, reliable, minimal estimate of 
the replication-competent proviral reservoir size. It has been helpful in 
measuring the stability of the reservoir over time. However, the assay is labor-
intensive, expensive, time-consuming, has a long turnaround time and requires 
a large number of cells to achieve a low limit of detection64,65,68,74,144,151,153. It 
also underestimates the size of the latent reservoir by ̴ 25-60-fold as not all 
replication-competent proviruses are induced in one round of activation70,73,116. 
Modifications have been made to the assay to reduce the duration and improve 
detection in shorter times such as moving from the ELISA to PCRs for HIV-1 
RNA, using the HIV infection permissive cells line MOLT-4 with CCR5 
expression and more152,154,155.  




As the proviral reservoir is dominated by defective proviruses, the switch to the 
use of these sensitive assays is not beneficial because some defective 
proviruses are capable of producing viral RNAs which will lead to 
overestimation of the reservoir size 70-73,152,154,156. 
These cons make it hard to use the QVOA in large studies such as clinical trials. 
However, it still remains a prime minimal estimate assay for studying the latent 
reservoir in HIV-1 infected people 64,65,68,86,144,151. 
 
➢ PCR- and sequencing- based: 
Quantitative PCR 
As culture-based assays like QVOA were laborious and complex, newer and 
simpler approaches to study the latent reservoir were developed, among them 
was the use of quantitative PCR assays68,144. qPCR is an assay that is 
performed on PBMCs or CD4 T cells to study the HIV-1 reservoir. The primer-
probes for this assay usually target conserved regions of genes like POL153,157. 
The results are interpreted by generating a standard curve from plasmid 
controls and calculating the relative quantities of the HIV-1 DNA 
copies144,153,157. The qPCR assays are sensitive, specific, cost-effective, have 
short turnaround times, are less complex, need smaller number of cells 
compared to QVOA, can be performed on different types of tissues/cells 
(primarily CD4 T cells/PBMCs) and sequencing of the proviruses detected is 
possible64,68,144,153,155.  




However, qPCR assays also have several disadvantages: Owing to the 
heterogeneity of the HIV-1 genome, qPCR assays are prone to primer-probe 
mismatches and it is difficult to identify whether a negative reaction is a true 
negative or a result of primer-probe mismatches65,144,153,155.   
 
Upon comparison with QVOA, it was found that the frequency of infected cells 
detected by qPCR was much higher than that of QVOA with a 300:1 ratio77,153.  
qPCR assays are unable to differentiate between defective and intact 
proviruses as well as integrated and unintegrated forms. Hence, they grossly 
overestimate the reservoir size.   
To counter the inability of standard PCRs to differentiate between integrated 
and non-integrated forms, a different type of qPCR was developed which uses 
the Alu sequences found in the human genome to help detect integrated HIV-
1 DNA. In Alu-PCR, one reaction is targeted towards the Alu regions in the 
human genome and the other reaction targets the GAG/LTR region to improve 
sensitivity158-162. The Alu-PCR is able to quantify the proviruses that are 
integrated68,144,153. As with qPCR, a standard curve is needed to quantify the 
results. This can be inefficient as not all Alu sequences will be in close proximity 
to the HIV-1 genome, therefore causing errors in detection, and the need for a 
correction factor to be calculated to account for this issue155,158,160,161,163,164.. 
 
Droplet digital PCR (ddPCR) 
Droplet digital PCRs are more sensitive than qPCRs and give absolute 
quantification of the reservoir; therefore they were developed as an alternative 
method to measure the reservoir145. ddPCR involves normalizing DNA to a 




particular concentration and adding this mix to special droplet generator oil that 
splits the liquid into nano-sized droplets such that each droplet (with or without 
a provirus) is its own PCR reaction145. Therefore, each provirus gets amplified, 
giving a more precise quantitative signal. ddPCR assays such as the GAG-LTR 
require a small sample size, are cost-effective, have a short turnaround time, 
are high-throughput, are more precise than qPCRs, are more tolerant to primer-
probe mismatches than qPCR, and can be used to test samples from various 
tissues64,65,68,144,145,151,155,165.  
However, the single-plex ddPCR does have issues that make it difficult to use 
this assay in cure studies: Single-plex ddPCR assays are unable to differentiate 
between defective and intact proviruses as well as integrated and unintegrated 
genomes, and thus grossly overestimate the size of the reservoir. In some 
cases, the no-template control shows false positive results. Based on the assay 
design, it is not possible to sequence any of the positive droplets, as the reader 
discards all the material. Owing to the use of primers and the heterogeneity of 
the HIV-1 genome, primer-probe mismatches are an issue, but they are better 
tolerated with the ddPCR vs the qPCR. However, based on the demerits it is 
stated that the qPCR is a better assay to measure the reservoir studies vs the 
ddPCR 64,65,68,144,151,153,155,165.   
 
Intact Proviral DNA Assay (multiplex ddPCR) 
The intact proviral DNA assay is a multi-plex ddPCR assay designed to study 
the latent reservoir. In the IPDA, two regions of the HIV-1 genome are targeted:                                                                                                                      
the packing sequence (psi, Ψ) upstream of the gag gene and the Rev Response 




Element (RRE) in the Env gene (Figure 3). These two regions were chosen 
based on near full-length genome sequence (nFGS) analysis and 
bioinformatics; it was shown that any deletions in these regions indicate a high 
probability that the virus is defective69. The IPDA also includes a double 
quencher probe for hypermutations near the env region (most variable region6); 
if there is a hypermutation present, that provirus will amplify but not fluoresce, 
excluding it from the positive droplets69.  
The results for the IPDA are displayed in a 2D amplitude plot where three 
quadrants represent a type of provirus: quadrant 1 - gag intact only + non 
hypermutated; quadrant 2: fully intact (gag + env); and quadrant 4 - env intact 
only. Quadrant 3 consists of proviruses that did not amplify with the IPDA 
primers69.  
This assay also accounts for the RNase P30 gene (RPP30), whose PCR 
reaction determines the number of cells analyzed and the shearing index.  
The primers for RPP30 bind at a distance of about 7kb from each other which 
is equivalent to the distance between the psi and RRE region. If the DNA gets 
fragmented during the processing for IPDA, it will be readily evident in the 
RPP30  PCR reaction by the presence of droplets in quadrants 1 and 469. Based 
on nFGS, one study found that only 2.4% of the reservoir is truly intact (i.e., 
lacking deletions, hypermutations, insertions.) while 97.6% is defective70,71. The 
IPDA can detect and exclude the 97% of the proviruses that are deemed 
defective by nFGS which is much higher in comparison to standard GAG-LTR 
PCR (30%) and the Alu PCR (tends to zero). As verified by nFGS, 70% of the 
proviruses that are deemed intact by the IPDA are truly intact compared to 10% 




detected by the Gag-LTR PCR.  Some of the main advantages of the IPDA are: 
Its exclusion criteria as mentioned earlier57,62,69,166; its ability to detect increase 
in infected cell frequency as a result of clonal expansion64,69,111,151,167; and the 
strong correlation with the data generated by the QVOA with respect to half-life 
of the reservoir and the changes in frequencies of intact proviruses. The IPDA 
can be applied to frozen cell pellets64 69,168.  It is cost-effective, requires small 
sample sizes and has a quick turnaround time64,69.   
However, the IPDA also has a few disadvantages:  It is currently optimized for 
HIV-1 subtype B only151,165,169,170. It cannot differentiate between replication-
competent and non-inducible intact proviruses since there could be defects in 
regions not overlapping the amplicons and the provirus could be integrated in 
an inactive gene69,151. It also overestimates (by ≈1.5 fold) the size of the 
reservoir for the same reason mentioned earlier. It also cannot differentiate 
between integrated and non-integrated forms of HIV-1 DNA, although the 
unintegrated forms are rare in patients on long-term effective ART, which adds 
to the overestimation of the size of the reservoir 64,69,70,151,169.  Primer-probe 
mismatches are possible due to single base mutations. However, since the 
IPDA is a multi-plex assay, primer-probe mismatches are readily identifiable vs 
standard PCRs62,69,169,171,172.   
Regardless, the advantages do outweigh the disadvantages and the IPDA is 
currently one of the best high-throughput PCR-based methods for 
differentiating between the intact and defective proviruses.  
 
 




Quadraplex quantitative PCR  
The quadraplex quantitative PCR assay also known as Q4PCR, was developed 
by Gaebler et al., using hundreds of proviral sequences from the Los Alamos 
Database to find the primers (in-silico). It consists of a limiting dilution of 
proviruses on which a long-distance PCR is performed paired with a multi-plex 
qPCR reaction where four regions of the HIV-1 genome: env, pol, psi (Ψ) and 
gag are interrogated, and the primers overlap the conserved portion of these 
regions169,173. The near full-length genome sequencing is only done on samples 
that show a positive reaction for two or more regions of the HIV-1 genome. This 
approach of sequence verification increases the probability of the assay to 
detect truly intact proviruses by eliminating the proviruses that are classified as 
intact in the qPCR but may have defects in the regions not overlapping the 
primers64,165,169,173. The Q4PCR is therefore a sensitive assay that can 
differentiate between intact and defective proviruses, and potentially can 
differentiate between integrated and unintegrated forms making it more specific 
than the IPDA64,165,169,173. For the Q4PCR, the cell input is detected by 
quantifying the amount of DNA added to the assay169,173. The Q4PCR however, 
is not a high-throughput assay as it involves near full-length genome 
sequencing, which is quite laborious.  
The limiting dilution followed by long distance PCR makes the turnaround time 
relatively longer than the IPDA. Since the Q4PCR is based on the use of primer-
probes, it is also subject to primer-probe mismatch issues, and was developed 
for subtype B. The Q4PCR can give insight into the integration site of the 
genome but cannot predict the inducibility of the provirus64,169,173.    





Sequencing approaches are extremely helpful in characterizing the reservoir of 
HIV-1  since they can help differentiate between defective and intact proviruses. 
There are several different techniques that are used to sequence the reservoir:  
• Near full-length individual proviral sequencing (FLIP-seq): The provirus is 
amplified using an outer PCR followed by nested PCRs in segments. 
Sanger sequencing or next generation sequencing (NGS) is performed. The 
FLIP-seq can determine whether a provirus is genetically intact or defective, 
the defects contained by the provirus, and the contribution of clonal 
expansion to reservoir maintainence64,86,103,151,174-176.  
• MIP-seq/FLIP seq: These are newer techniques that involve amplifying the 
proviruses using multiple displacement amplification (MDA) followed by 
NGS and integration site analysis (MIP-seq). MIP-seq provides information 
about the intactness of the provirus as well as chromosomal integration 
site64,103,151,177 
The disadvantages of sequencing techniques are that they are not high 
throughput; they are labor intensive and expensive; and in some cases, custom 
primers may be required64,86,151,175. However, sequencing techniques are able 
to characterize the reservoir well and can be used to supplement assays such 
as IPDA to characterize the reservoir. Gaebler et al., have merged a PCR-
based method of measuring the reservoir to sequencing to help determine the 
replication competency of the proviruses in addition to their intactness and the 
size of the reservoir169,173.   




➢ Assays that measure the concentration of transcriptionally/translationally 
competent viruses 
Tat/Rev Induced Limiting Dilution Assay  
The Tat/Rev induced limiting dilution assay (TILDA)  was developed to measure 
multiply spliced viral transcripts (transcriptionally competent) that can be 
produced by the latent reservoir upon stimulation using mitogens such as PMA 
and ionomycin 178. In the TILDA, infected cells are stimulated with mitogens, 
and different dilutions of these activated cells are prepared followed by 
performance of a nested PCR for Tat/Rev regions178. It has been shown that 
Tat/Rev deletions are common in defective proviruses, which implies that 
several defective proviruses may not amplify these regions73,178. This approach 
of performing a PCR after culture permits skipping the RNA extraction step178. 
On comparing the frequency of latently infected CD4 T cells between TILDA, 
QVOA and PCR assays it was noted that the TILDA gave 48-fold higher values 
than QVOA but 6-27-fold lower values than PCR assays65,178. TILDA is a 
relatively simple assay compared to the QVOA as it requires less than a million 
cells, has a short turnaround time of 2 days, and RNA extraction is not 
needed64,155,178.  It is sensitive, reproducible, and specific to HIV-1178.  
The TILDA, like the QVOA, depends on one round of stimulation, which may 
lead to underestimation of the reservoir144,155,178,179. However, since defective 
proviruses with no defects in the tat-rev regions also produce proteins and 
therefore viral transcripts, the TILDA is unable to differentiate the two and may 
overestimate the size of the reservoir64,71-73,156,178.  




This may be accounted for by using spontaneous production of transcripts by 
adding Tat to the cells rather than mitogens178,180-182. The TILDA is also more 
labor- and cost-intensive than PCR assays; however, it is more discriminating 




Reservoir studies in Adult HIV-1 Infections using the IPDA.  
Prior to the development of the IPDA, in studies done on adults who initiated 
ART during acute infection,  across different cohorts, the following observations 
were made about the benefits of early effective ART vs treatment during chronic 
infection: reductions in the size of the HIV-1 reservoir56,58,78,183-187, rapid immune 
reconstitution58 and lower immune activation of T cells56. All of these studies 
were done using different assays54. Some studies showed that the reservoir 
decayed faster in adults who started ART early during the infection61,184.  
 
 
Figure 3. IPDA primer binding sites 
The IPDA primers (in green) bind in the packaging signal region of the GAG gene 
and the Rev response element in the Env gene69. Created with Inkscape by Dr. Adit 
Dhummakupt. 




The development of the IPDA provided a high-throughput method to elucidate 
the dynamics of the different HIV-1 proviral species which would be helpful in 
informing cure strategies.   
In a recent study where IPDA was applied to 81 participants who started ART 
during chronic infection62, the authors noted differences in the decay rates 
between the two proviral species: intact and defective HIV-1 DNA. Over a 
course of the study, they observed that the intact proviruses decayed much 
faster than the defective HIV-1 proviruses, with a rate of -15.7 % per year for 
intact proviruses, in the first 7 years of virologic suppression (VS). In contrast, 
some participants demonstrated an expansion in 3’ deleted/hypermutated HIV-
1 DNA and some showed an expansion in the 5’ deleted HIV-1 DNA population 
during the first seven years after VS. After the seven-year inflexion point, the 
rates of decay decreased for all species, but were still higher for intact 
proviruses compared to defective HIV-1 proviruses. The main conclusion was 
that the decay rates differed between the proviral species with intact HIV-1 DNA 
decaying much faster than the defective HIV-1 species especially in the first 7 
years after VS62.  
This suggests that the intact replication competent proviruses stochastically 
reactivate, express viral proteins and are killed either by the HIV specific 
immune responses or by viral cytopathic effects62. However, the infection of 
new cells by the virions produced by this reactivation is prevented by ART.  
In a second study57 on 44 participants on effective ART over a course of 12 
years after ART, samples were collected at a median of 7.1 years after ART 
initiation (time point 1), 3.7 years after time point 1 and 1.8 years after time point 




2. It was observed that although the intact proviral reservoir declined, the 
defective HIV-1 proviral reservoir either expanded, remained stable or declined. 
Owing to this, the total HIV-1 DNA remained relatively stable over the course 
of effective ART, even though the intact proviral reservoir seemingly declined. 
They also observed that the median intact copies/million CD4 T cells decreased 
from time point 1 (median 7.1 years; T1) to time point 3 (median 12.6 years; 
T3). The %intact fell from 9.8% at T1, to 5.8% at T3 and, some of the 
participants showed an increase in the 3’ deleted/hypermutated or 5’ deleted 
HIV- 1 proviruses while some showed a decline, between T1-T3.  
These data support the idea that the replication-competent proviruses 
stochastically reactivate, express proteins and are then eliminated by the HIV 
specific immune responses or are killed as a result of viral cytopathic effects. 
Defective proviruses do produce proteins and express them on the surface of 
the cells; this is observed with 5’ deleted proviruses which can decline slowly in 
some cases, but their loss can be compensated by expansion or stability of 3’ 
deleted/hypermutated proviruses. This also supports the idea that the defective 
proviruses expand over time on suppressive ART allowing the total HIV-1 DNA 
concentration to remain stable over time167,188.   
Altogether this study showed that while the intact proviruses decay over time 
on ART, the defective proviruses continue to expand and dominate the 
reservoir  landscape. Over the course of the study, median change per year for 
the 3’ deleted/hypermutated HIV-1 proviruses, was found to be zero. This 
proved that little to no net change was observed for this set of proviruses57.  
 




A few interesting observations in the study were:  
1) Low CD4+ T cell counts prior to ART initiation were found to be associated 
with higher total HIV-1 DNA copies and a higher proportion of defective HIV-
1 DNA copies on effective ART. The authors speculated that this was a 
result of longer untreated infection which permitted the virus to accumulate 
over time with predominantly defective HIV-1 proviral species.  
2) Lack of decline of defective HIV-1 proviruses in the face of declining intact 
was speculated to be caused by multiple factors such as integration of intact 
proviruses into transcriptionally active sites permitting expression of viral 
proteins/virion release and clearance by the immune system/viral cytopathic 
effects. Expansion of cells carrying the defective HIV-1 proviruses could 
dilute the intact HIV-1 proviral reservoir (being eliminated) making it appear 
as though the defective HIV-1 proviruses remain stable over time. HIV-1 is 
known to integrate into genes involved in cell cycle control which could 
explain why proliferation may occur111,167. 
3) The half-life of the intact proviral reservoir detected by IPDA (7.1 years) was 
much longer than that determined by the QVOA (3.6-3.7 years), which could 
indicate that a portion of the intact proviruses have deep latency features 
50,90. This has implications in terms of clearance of the reservoir.  
Will these proviruses be reactivated after multiple rounds of stimulation?  
The answer to the above question was found in another study done on 12 adults 
with HIV-1, on long-term suppressive ART, who maintained plasma viral 
load<20 copies/mL on ART for >6 months116. In this study, Hosmane et al., 




used a modified version of the QVOA where instead of just one round of 
stimulation, four rounds of stimulation were done.  
They observed that during the first round of stimulation only 60% of the culture 
were positive for p24 even though >99% of the resting CD4 T cells had 
proliferated which would indicate that cells without replication-competent 
proviruses might also have proliferated. However, each additional round of 
stimulation was beneficial in reactivating more viruses that would not have been 
reactivated without the additional stimulation116. This is an important finding as 
it proves that the latent reservoir is capable of proliferating without reactivation 
on initial exposure to mitogens but upon additional stimulus, it reactivates to 
produce virions. The results of this study support the following ideas: 1) the 
reservoir size lies in between that measured by assays such as IPDA and 
QVOA, and more than one assay will be required to quantify the effect of cure 
strategies on the reservoir; and 2) the curative strategies will need to account 
for the lack of viral gene expression by a proportion of the replication-competent 
proviruses in spite of proliferation.  
Since the IPDA is a relatively new assay, Simonetti et al., sought to determine 
the performance characteristics of the IPDA by applying it to 400 adults on ART 
from different cohort studies171. The main observations were as follows:  
1. Of the three DNA species, the proviral load was the lowest for the intact 
proviruses and only 8% of the total HIV-1 DNA was composed of intact 
proviruses similar to what was seen in the study by Gandhi et al.,171,189. 
These observations confirmed that on ART, the proviral landscape is 
dominated by cells carrying defective proviruses while the frequencies of 




cells carrying intact proviruses are relatively low. The authors found the ratio 
of defective to intact proviruses to be  ̴12.5:1171.  
2. The frequencies of intact proviruses reported by the IPDA are 50-fold 
greater than that observed in QVOA and 12.5-fold lower than the total 
frequency of infected cells.  
Therefore, the IPDA gives a better estimate of the reservoir size than qPCRs 
(overestimation) and QVOA (underestimation). However, some of the 
proviruses labelled as intact by the IPDA may have minor defects in regions 
not overlapping with the amplicons of the IPDA171 which could affect their 
ability to reactivate and produce infectious virus.  
3. Since the IPDA uses primer-probes for detection, it is susceptible to 
sequence polymorphisms in the regions that overlap the primer-probe 
binding sites. Bruner et al., had shown that 4% of proviruses are likely to not 
be amplified due to defects in the regions overlapping both the primer-probe 
sets i.e., gag (psi) and env69. This meant that only 96% of the proviruses 
would be detected by the IPDA. Of these 96%, Simonetti et al., observed 
that a total of 6.3% of participants (25/400), out of 400, showed amplicon 
signal failure with 3.5% (14/400) showing amplicon signal failure for psi and 
2.8% (11/400) showing amplicon signal failure. However, since the IPDA is 
a multi-plex PCR assay, it was easy to catch the signal failure relative to 
single-plex PCR assays. This was resolved by developing individual primer-
probe sets for the participants that showed signal failure. This was an 
important observation as it showed that sequence polymorphisms are 
common and expected in studies involving large cohorts and identifying 




common polymorphisms could allow us to develop primer-probes that are 
less susceptible to signal failure171.  
In another study, Gaebler et al., sought to compare the IPDA to an assay 
developed in their laboratory known as the quantitative quadraplex PCR assay  
(Q4PCR)169,173. They applied the IPDA and Q4PCR to 39 participants on long-
term suppressive ART (median of 8.4 years). They observed the following: 
1. The frequency of cells containing intact proviruses detected by Q4PCR 
(median of 5 copies/million CD4 T cells) was between that detected by IPDA 
(median of 65 copies/million CD4 T cells) and QVOA (median of 0.6 
infectious units/million CD4 T cells)169.  
2.  A positive correlation between the two assays was observed with the 
caveat that IPDA detects almost 19-fold higher frequencies of intact 
proviruses than Q4PCR does. This was attributed to: a) the inefficiency of 
the initial long-range PCR amplification; b) the misclassification of 
proviruses that may have defects in regions not overlapping the IPDA 
primer-probes as intact by the IPDA; and c) cell normalization methods for 
both the assays169.  
3. Using Q4PCR, they were able to show the high specificity of psi and env 
primer-probe combinations (same as that used in IPDA) for excluding 
defective proviruses. Of the 3 participants that were shown to belong to 
another subtype by the Q4PCR, the IPDA showed primer-probe 
mismatches in the env region reenforcing the idea that IPDA, which was 
developed for subtype B, must be optimized for other subtypes before 
use169.  




4. Amplicon signal failure was observed in 18% of the participants (7/39) for 
the IPDA, while the Q4PCR was unable to retrieve intact sequences from 
20.5% of the participants  (8/39).  
The main conclusion was that the differences in the two assays continue to 
support the idea that the proviral landscape is dominated by defective 
proviruses with low frequencies of intact proviruses and using the two assays 
together would help provide a deeper characterization of the reservoir169. 
In a study by Falcinelli et al., the authors sought to compare the IPDA to the 
QVOA. They tested resting CD4 T cells from 83 participants on suppressive 
ART in a cross-sectional and longitudinal study. Of the 83 participants, 7 (8.4%) 
showed primer-probe mismatches. Of the other 76, 16 were treated during 
acute infection and 60 were treated during the chronic infection.   
The cross-sectional study revealed the following: 
1. As expected, the frequencies of proviruses were the lowest for QVOA, 
followed by intact, 5’ deleted, 3’ deleted/hypermutated and total HIV-1 DNA. 
A median of 11.6% of total proviruses consisted of intact proviruses. 
2. In the early-treated participants, the proportion of intact DNA in the HIV-1 
reservoir was much higher than that in chronically infected participants. This 
could indicate that the starting levels of intact HIV-1 DNA in early-treated 
participants are higher. Another possibility was that the IPDA was developed 
for detection of proviruses during treatment of chronic infection. There are 
differences in hypermutations and deletions between early treated and late 
treated participants. These differences could have affected the ability of the 
IPDA to detect intact proviruses in acute infections, to confirm this idea, 
more research would be required.  




3. When a correlation with QVOA was run, it was found that intact and total 
HIV-1 DNA had a better association with replication-competent virus 
outgrowth than with defective proviruses. This was to be expected since the 
IPDA is capable of detecting over 96% of the intact proviruses. 
In the longitudinal analysis, the following observations were made: 
1. In early treated participants, the frequency of decrease for intact proviruses 
detected by IPDA corresponded to that of the replication-competent 
proviruses detected by QVOA with increasing durations of suppression. The 
frequencies of defective proviruses were variable and showed either 
expansion, decline or stability with increasing duration of suppression. This 
observation supported the idea that defective proviruses dominate the 
proviral landscape during long-term treatment.  
2. In participants who were treated during chronic infections, the intact 
proviruses as quantified by the IPDA showed two trends. In most cases, the 
intact proviruses declined in parallel to the replication-competent proviruses; 
however, in a few cases, the intact proviruses remained stable as the 
replication-competent proviruses declined. The reasons for this could be 
variance in the assay or clonal expansion of intact proviruses176,190. Clonal 
expansion of intact proviruses without reactivation of the replication-
competent proviruses is possible, as discussed above, and could contribute 
to the persistence of the replication-competent reservoir116. 
The main conclusions of the study were: intact proviruses are selectively 
eliminated, the intact proviral frequencies detected by the IPDA correlate well 
with those detected by QVOA; the percent decrease in intact proviruses as 




detected by the IPDA parallels percent decrease of replication-competent 
proviruses seen with QVOA; and in comparison, to the other assays, the results 
of the IPDA provide a better upper limit to the size of the reservoir.  
In conclusion, the IPDA has proven to be a beneficial high-throughput tool to 
quantify and characterize the dynamics of the reservoir in adults.  
 
Reservoir studies in Pediatric HIV-1 Infections 
The latent reservoir in pediatric infections was discovered in 2000 using the 
QVOA74. Since then, many studies have been performed to characterize the 
reservoir and the effect of ART on the reservoir36,55,59,60,63,94,179,191-220.  
Initially the studies describing the decay dynamics of the reservoir in perinatal 
infections were performed on samples from participants who were treated 
during chronic infection (>2years after infection)208,211. Initiation of ART in 
children lead to a biphasic decay where the rate of decay was rapid prior to the 
inflexion point, 4 weeks after ART initiation for study by De Rossi et al., after 
which the rate of decay slowed down218. 
In 2005, a clinical trial namely Children with HIV early antiretroviral therapy 
(CHER) was started203. In this trial, children aged 6 -12 weeks (median age = 
7.4 weeks) were divided into two arms: one arm deferred therapy and one arm 
received time limited ART for either 40 or 96 weeks and then ART was 
interrupted.  
After a median follow up of 40 weeks, it was observed that: 1) mortality rates 
decreased by 76% for early treated vs deferred treatment; 2) the CD4 T cells 




were reconstituted in the early treated group vs the deferred treatment; and 3) 
the disease progression declined by 75% for early treated participants vs 
deferred treatment203.  
The results of this seminal study were supported by other observational studies 
where it was found that early ART: 1) reduced the chances of disease 
progression191,200,214; 2) The proviral loads for early treated participants were 
lower as compared to those who received deferred treatment191; and 3) the 
levels of CD4 T cells were higher in early treated participants compared to those 
who received deferred treatment191. This set the stage for changing  
recommendations for timing of ART initiation set by the WHO221.  
Following these new guidelines, the field moved towards early treatment and in 
some cases very early treatment (e.g., Mississippi baby was treated within 30 
hours of birth92). The data from these studies, across several cohorts, subtypes 
and durations of suppression supported the following observations: 1) the 
reservoir size in early treated participants was smaller than that observed in 
late treated participants216,220,222; 2) the proviral loads were very low and, in 
many cases, undetectable within months of virologic suppression for the early 
treated participants compared to the late treated55,59,191,196,199,201,202,207;  3) early 
treatment led to early suppression of viremia, thus reducing the size of the 
reservoir and immune activation caused by HIV-1 replication and antigen 
exposure199,201,219; and 4) disease progression was curtailed215.   
However, the reason for decrease in the size of the reservoir was not well 
elucidated therefore, to understand what was going on, in a seminal study, 
Uprety et al., studied the decay dynamics of the reservoir in long-term 




suppressed children. In their study, Uprety et al., looked at two groups stratified 
by age at virologic suppression, in the Pediatric HIV AIDS Cohort Study60. Both 
groups had participants that were early treated but one group consisted of 
participants that were suppressed before one year of age and the other group 
consisted of participants suppressed between 1-5 years of age. It was observed 
that at the time of suppression, both the groups had similar amounts of HIV-1 
DNA as detected by the Pol-LTR ddPCR assay. However, within the first two 
years of virologic suppression (VS), the HIV-1 DNA decayed much faster in 
early suppressed group than it did in the later suppressed group60. This 
explained the reason for the eventual smaller reservoir sizes in early treated 
children.  
As the study used a total HIV-1 DNA measure, the reason for the faster decay 
of HIV-1 DNA in the early suppressed group was not identified60. This is where 
the IPDA assay could bridge the gap, by allowing characterization of the HIV-1 
DNA species and providing a rationale for the faster decline of HIV-1 DNA in 
the first 2 years after VS with early treatment60,69. The studies done on the 
reservoirs in perinatal HIV-1 infections have applied assays such as 
QVOA55,63,193,198, near full-length genome sequencing193,195,219,qPCR or ddPCR 
of the gag/pol/LTR59,60,63,193,196,199,202,205,215,216,219,220. 
QVOA as mentioned earlier gives the minimum estimate of the size of the 
reservoir and requires large volumes of blood, which makes it difficult to study 
the reservoir in very early treated pediatric participants. It is also not feasible 
for large cohort studies64,65,68,144,148,151,153,155. The near-full length genome 
sequence (nFGS) on the other hand, has shown that there is a paucity of intact 




proviruses in early treated children193,195. However, the long-distance PCR of 
the nFGS is inefficient and could preferentially amplify shorter strands of 
defective proviruses, leading to an underestimation of the intact 
proviruses64,86,151,169,173,175. Therefore, nFGS is not well suited to accurately 
quantify and characterize the reservoir in children. 
Total HIV-1 DNA measures such as with qPCR or ddPCR target single-
amplicon regions such as the gag, pol, LTR regions 
59,60,64,65,68,144,145,151,153,155,165,205. These assays can be particularly useful in 
measuring the reservoir size during long-term suppressive therapy when the 
proviral loads fall to exceedingly low levels, below 5 HIV-1 DNA copies/million 
PBMCs and for which assay optimization for detection across all subtypes are 
critical59,60,63,196,205. However, total HIV-1 DNA assays overestimate the size of 
the reservoir as they also quantify defective proviruses which are known to 
accumulate as the duration of suppression increases64,65,68,144,145,151,153,155,165. 
Feasibility of measuring the proviral reservoir in children is important; however, 
we need to improve the understanding of the mechanism behind differential 
decay dynamics of the reservoir in early vs late treated children. 
The application of the IPDA to perinatal infections will help us to understand the 
cause behind differential decay dynamics in early and late treated participants 
by characterizing the reservoir. What leads to the differential decay of the 
reservoir in early vs late treated especially when they start out with the same 
proviral loads at the time of suppression?60 Is it the clearance of the intact 
proviruses? Or does clonal expansion of the defective proviruses dilute the 




reservoir?70,167 The questions can be answered by the IPDA and will inform the 
development of remission strategies.   
To our knowledge, no study has been done on pediatric HIV-1 infections using 
the IPDA, and the present study is the first preliminary study that will allow us 
to understand the dynamics of the different species of HIV-1 in the reservoir as 
a function of age at virologic suppression and duration of virologic suppression.  
 
Study Aims: 
1. Optimize and validate the Intact proviral DNA assay for Pediatric samples 
where cell availability for study is limited. 
 
2. Estimate the proviral reservoir size, and the distribution of total, intact, and 
3’ deleted/hypermutated and 5’ deleted HIV-1 proviral genomes during 
effective ART in children and adolescents living with perinatally acquired 
HIV-1.  
 
3. Compare the proviral reservoir size of total, intact, and 3’ 
deleted/hypermutated and 5’ deleted HIV-1 proviral genomes as a function 
of age at virologic suppression and duration of virologic control in children 
and adolescents living with perinatal HIV-1.   




II. Materials and Methods 
 
1. Establishing an Internal Standard for the IPDA 
The JLAT cell line was obtained from the NIH AIDS reagent program. JLAT 
cells also known as Jurkat cells are a cell line derived from a person with T cell 
leukemia 223. A derivative of the JLAT cell line was developed by Jordan et al., 
to study the HIV-1 reservoir in an in-vitro model224. An HIV-1 genome was 
inserted into the cell line and was tagged with green fluorescent protein. The 
JLAT cells do not produce infectious virus owing to a frameshift mutation in the 
env region224. However, this cell line is ideal for IPDA since each cell only 
carries one copy of the HIV-1 genome, permitting its use for quantitative 
studies224,225. The methods described below for maintaining JLAT cells culture 
were optimized in the laboratory69.  
 
1.1. Preparation of JLATS for testing 
Thawed JLAT cells were spun at 300 x g for 10 min using the Beckman Coulter 
Allegra X14R, the supernatant was decanted, and the cell pellet was 
resuspended in 10mL of Thawing media (TM; 50% FBS (Sigma Aldrich; 
#19G462) + 50% RPMI 1640 (Gibco; #61870-036)). The cells were spun again 
at 300 x g for 10 min, the supernatant was decanted, and the cell pellet was 
resuspended in 10mL of JLAT media (RPMI 1640 + 10% heat inactivated Fetal 
Bovine Serum (FBS) + 1% Pen Strep (Gibco; #15140-122)). The cell count and 
viability check were then performed using a 1:2 dilution with trypan blue (Gibco; 
15250-061).  




10μL of this trypan blue:cells mix was added to the hemocytometer (Bulldog 
Bio; #DHC N005). The cell count was determined by counting the number of 
JLAT cells in the four WBC quadrants of the hemocytometer slide. After this, 
cells/mL had to be determined as well as the viability of the cells. The formula 






× 10,000 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟, where C = Number of cells, 4 = number of 
quadrants and 10,000 represents the volume of each quadrant in mL 
𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = (
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑙𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠
𝑇𝑜𝑡𝑎𝑙 𝐶𝑒𝑙𝑙𝑠
) ∗ 100 
Based on the cell count, the cells were spun at 300 x g for 10 min and then 
resuspended in the appropriate amount of JLAT media to achieve a 
concentration of 1-3*105 cells/mL. The cells were incubated in the 37oC 
incubator, 5% CO2, humidified air, for 48 hours.  
 
1.2. Passaging of JLATS 
The cell density and viability of the JLATs were checked every 2-3 days using 
trypan-blue exclusion dye staining. The cell count and viability check were  
performed using a 1:2 dilution of JLATs to trypan blue as described above. If 
the slide was too crowded (i.e., more than 100 cells in one WBC quadrant of 
the hemocytometer), a 1:10 dilution of cells to trypan blue was created. The cell 
count was performed and the viability of the JLAT cells was determined as 
described above. We determined that the optimal cell concentration had to be 
between 2*105 cells/mL and 2*106 cell/mL to ensure that the JLATs did not start 
losing viability. 




If the cell count was close to 5 million cells/mL, all the cells were passaged and 
split into the appropriate number of flasks. The optimal concentration of the cells 
after passaging and splitting was determined to be 1-3*105 cells/mL. The flasks 
were incubated in the 370C incubator, 5% CO2 for 48 hours. 
 
1.3. Maintaining frozen stocks of JLATS 
The cell density and viability of the JLATs were checked every 2-3 days as 
described above. When the cell density was approximately 5*106 cells/mL 
frozen stocks of the JLAT cells were created by spinning down the cells, adding 
freezer medium (FBS: 90% + DMSO:10%) to the cells. The cell suspension was 
then dispensed in 1mL aliquots into cryovials which were placed into Mr. Frosty 
(slow cooling container filled with isopropyl alcohol to achieve a cooling rate of 
1oC/min; Nalgene; #5100-0001) and then kept in the -800C freezer overnight. 
The following day the vials were placed in the vapor phase nitrogen tank for 
long-term storage. 
 
2. Preparation of JLAT Standards 
For preparing the JLAT standards, a fresh blood bag was ordered from the New 
York Blood Centre on the day of preparation to have stocks (pellets of 5 million 
cells) of human peripheral blood mononuclear cells (PBMCs) to spike with 
known concentrations of JLAT cells. The blood from the blood bag was 
overlayed on Ficoll and spun at 400 x g for 25 min using the Beckman Coulter 
Allegra X14R. After the blood was divided into the four layers, the buffy layer 
containing the PBMCs was extracted. The PBMCs were then washed (wash 




media: phosphate buffered saline (PBS), pH7.4, 2% heat inactivated new-born 
calf serum, 0.1% glucose, 20U/mL penicillin, 20µg/mL streptomycin, 12mM 
HEPES, pH7.4) and the cell count was performed as described above.  
Once the cell count was determined, wash media was added to the PBMCs to 
achieve a concentration of 10 million PBMCs/mL which was confirmed with 
another cell count.  
Based on the final count, the number of aliquots for JLAT standards that could 
be prepared was determined. 4mL of the PBMCs was aliquoted out and split 
into tubes containing 0.3mL of the PBMCs (3 million cells). The tubes were kept 
aside. This was the I9 standard (no HIV-1 DNA standard).  
Next, the JLATs were spun at 300 x g for 10 min, and the supernatant was 
decanted. The cell pellet was resuspended in wash media to achieve a 
concentration of 1 million JLATs/mL, this was verified by another cell count. To 
begin generating the standards, 4 mL of the 10 million PBMCs/mL stock 
(corresponding to 40 million PBMCs) was taken and added to a 15mL conical 
tube. To this 0.04mL of the 1 million JLAT cells/mL stock (corresponding to 
40,000 JLAT cells) was added to give a solution containing 1000 JLAT 
cells/million PBMCs. The remaining standards were prepared using the table 
below: 





Each sample was mixed well to ensure even JLAT distribution. Once the 
dilutions were ready, the cells for each dilution were aliquoted out as pellets of 
either 5 million or 3 million cells  (PBMCs+ JLATs). The tubes were then spun 
at 3000 rpm for 5 min using the tabletop Eppendorf Centrifuge 5430R and most 
of the supernatant was removed using a pipette, leaving behind about 50µL. 
The tubes were stored at -800C in a box. 
  
 
Table 1: JLAT Standard Preparation 
The dilution factors in the table refer to the dilution that was made from the 
respective columns for the next concentration. In column 1, 10 was the dilution we 
















(1.25) I9 (0) 
Initial volume of 
PBMCS (mL) 4 3.6 3.1 2.4 2 2 2 4 
Volume of 
previous dilution 
added to the tube 
(mL) 
- 
0.4 0.9 1.6 2 2 2 
- 
Dilution Factor 10 4 2.5 1.5 2 2 2 0 
Total Volume 








PBMCS 1000 100 25 10 5 2.5 1.25 0 
* To I1, 0.04mL of 1 million JLATs/mL stock was added. 
 




3. Isolation of Genomic DNA from JLAT/PBMC Standards  
The Qiagen Qi-AMP Blood DNA Midi Kit (#51183; Qiagen, Valencia, California) 
was used to isolate genomic DNA from the JLAT standards.  
Once the tubes containing the pellets were labelled, 1.2mL of Buffer AL (Lysis 
Buffer; provided in the kit) was added to each cell pellet to reduce the chances 
of breakdown of DNA by DNAses or shearing. 100µL reconstituted Proteinase 
K (provided in the kit) was pipetted out into each of the sterile 15mL centrifuge 
Tube (VWR). The contents of the original cell tubes were transferred into the 
respective 15mL centrifuge tubes. The cell tubes were then rinsed with 1mL 1X 
PBS (Quality Biological; #114-058-101) and the original cell tubes were 
discarded. The 15mL centrifuge tubes were then pulse vortexed using the 
vortex mixer (Fisher Scientific Vortex Mixer) and were placed upright in the 
70oC Isotemp Waterbath (Fisher Scientific Isotemp Water bath) for 10 min.  
After the incubation, the tubes were spun at 3200 rpm for 3 min using the Jouan 
C3i tabletop centrifuge. Post-centrifugation, 1.2mL of 100% ethanol (Fisher 
Bioreagents; #BP2818-500) at room temperature was added to each of the 
tubes. The tubes were then pulse vortexed and spun down at 3200 rpm for 3 
min.                                                                                                                                                                        
The contents of each standard’s tube were transferred carefully into the 
respective Qiagen MIDI centrifuge tubes with spin column. The tubes with spin 
columns were spun at 3200 rpm for 5 min. For each standard, the spin columns 
were carefully taken out, and the flow through was discarded. The collection 
tubes were retained, and the spin columns were re-inserted into their respective 
tubes. 2mL of Buffer AW1(provided in the kit) was added into each spin column 
followed by a spin (4000 rpm for 4 min), and then 2mL of Buffer AW2 (provided 




in the kit) was added into the spin columns. The tubes were spun at 4000 rpm 
for 18 min and then again for an additional 4 min. The spin columns were then 
taken out and placed into new 15 mL MIDI centrifuge tubes. Next, 200µL Buffer 
AE (provided in the kit) was added to the spin columns and the buffer was 
allowed to infiltrate the filter before centrifuging.  
The new tubes with spin columns were spun at 4000 rpm for 4 min. This step 
was repeated 4 times for a total of 1mL eluate. 1µL of thawed glycogen 
(Thermofisher Scientific, #R0561) was added to two pre-labeled 1.5mL 
microcentrifuge tubes for each standard while all tubes were still placed on ice. 
Next, 500µL of eluted DNA was transferred to the respectively labelled two 
1.5mL microcentrifuge tubes. 50µL 3M sodium acetate (Quality Biological; 
#351-035-721) and 1mL cold 100% Ethanol were added to each of the 1.5mL 
tubes containing eluted DNA. The tubes were gently inverted to promote  mixing 
and were then stored overnight in a  -20°C freezer. 
The tubes were taken out from the freezer and spun in an Eppendorf 
Refrigerated Microcentrifuge 5417R at 40C, 14,000 rpm for 30 min. After the 
spin, the supernatant was decanted, and the DNA pellets for each of the 
samples respectively were combined into one tube using 70% ethanol. The 
tubes containing the pellets were centrifuged at 14,000 rpm (room-temperature) 
for 2 min and the supernatant was decanted. The tubes without pellets were 
rinsed with 1mL 70% Ethanol and the contents were added to the tubes with 
the pellets. The tubes containing the pellets were spun at 14,000 rpm (room-
temperature) for 2 min and the supernatant was decanted. The tubes were spun 
again at 14,000 rpm (room-temperature) for 1 min, and any remaining 
supernatant was removed carefully.  




The DNA pellet was left to air-dry. Once the alcohol had evaporated, the DNA 
pellet was resuspended in 50µL of Buffer AE.  
The optical density was measured on the Thermo Scientific Nanodrop Lite 
Spectrophotometer and recorded. The tubes were then stored in the working 
box located in the -200C freezer 60,205.  
The Qiagen Gentra Puregene Blood kit (Cat # 158467; Qiagen, Valencia, 
California) was used to isolate genomic DNA to reduce shearing.   
The tubes containing the pellets were labeled and 0.6mL of cell lysis solution 
(provided in the kit) was added to each pellet to reduce the chances of 
breakdown of DNA by DNAses or shearing. The suspension was mixed by 
pipetting. To this, 3µL RNase A solution (provided in the kit) was added and the 
tubes were mixed by inversion 25 times. The tubes were incubated for 5 min at 
370C followed by incubation on ice for 2 min. 200µL of Protein Precipitation 
Solution (provided in kit) was added and the tubes were vortexed vigorously 
and spun at 16000 x g for 3 min using the tabletop Eppendorf Centrifuge 5451D. 
600µL  of isopropanol was added to fresh 1.5mL microcentrifuge tubes and the 
supernatants from each of the tubes were transferred to the respective tubes 
containing isopropanol. The tubes were mixed by gently inverting them 50 times 
and were then spun at 16000 x g for 1 minute. The supernatant was discarded, 
and the remaining liquid was drained from the tube onto an absorbent paper. 
300µL of ethanol was added to the tubes, the contents were mixed, the tubes 
were spun at 16000 x g for 1 min and the supernatant was discarded. The 
ethanol wash was repeated one more time. After the 2nd wash, the pellet was 
allowed to air dry for 5 min. Next 50µL of DNA hydration solution (provided in 
the kit) was added, the tubes were vortexed for 5 seconds and incubated at  




65°C for 1 h using the Eppendorf Thermomixer 5350. This was followed by 
overnight incubation at room temperature with gentle shaking. The samples 
were then spun at 16000 x g for 1 min and stored in the working box located in 
the -200C freezer. 
For each Pediatric HIV/AIDS Cohort Study (PHACS) sample being tested, four 
controls were required, two high concentration controls I1 and I2 with 1000 and 
100 HIV-1 DNA copies/million PBMCs respectively, a negative control I9 with 
no HIV-1 DNA copies/million PBMCs and a no template control (NTC). Since 
the DNA from the PHACS samples was previously isolated, only the controls 
for the same were isolated using the JLAT standard.   
 
4. Intact Proviral DNA Assay  
The Intact Proviral DNA Assay (IPDA) is a multiplex droplet digital PCR 
(ddPCR) assay69. With ddPCR, every droplet is considered as an individual 
PCR (even though not every droplet has a proviral genome); therefore, each 
droplet is analyzed individually. This provides higher resolution as compared to 
the qPCR.145 In the IPDA , the first reaction is targeted to two highly conserved 
genes in the HIV-1 genome called psi (packing signal) upstream of the gag 
gene and the rev response element (RRE) in env.69 The second reaction is 
targeted to the housekeeping gene RNAse P30 (RPP30) for determining the 
number of cells analyzed as well as to provide estimates of DNA 
shearing60,69,145. The primer-probe sequences for RPP30 were based on 
previously published methods by Kinloch et al172. 
  




4.1  Preparing the Master Mix 
Primer Probe Preparation 
The primer and probe were reconstituted to a concentration of 100µM before 
use. Table 2 summarizes the primer-probe sequences used in the assay. The 
20X primer-probe solutions derived from the 100µM solutions were used in the 
assay.  
Each sample was run in 8 replicates to assess for gag (Psi), env and 
hypermutations; one replicate reaction was set up for RPP30; along with the 
controls (I9) and no template control (NTC); these were run in 4 replicates. In 
ddPCR, the data from droplets in every well for each sample is aggregated 
using Poisson distribution to give a single value. 
The master mix was prepared by taking the desired volume (based on the 
number of replicates) of: ddPCR Supermix (Bio-Rad, #186-3024) + 20X primer 
probe solutions + DNase/RNase free water. This mix was then vortexed and 
spun briefly. 
4.3 Preparation of the ddPCR Plate (Assay Master Mix + Samples)  
The samples for the GAG/ENV/Hypermut PCR were prepared by mixing 135µL  
of the GAG/ENV/Hypermut master mix and 45µL of normalized DNA.  
The controls for this PCR were prepared by mixing 22.5µL of the 
GAG/ENV/Hypermut master mix and 7.5µL of normalized DNA. The samples 
for the RPP30 PCR were prepared by mixing 22.5µL of the RPP30 master mix 
and 7.5µL of normalized DNA for samples and controls.     
 






Table 2: Primer Probe Sequences for IPDA172 
 
The table shows the different sequences used by the PCR reaction. The GAG and 
ENV probes fluoresce in different channels based on the presence of the amplicon 
within a given droplet. The hypermutation probe is a double quencher probe and 




















Forward 5’ – TCT-CGA-CGC-AGG-ACT-CG – 3’ 
IPDA GAG
Rv









































Forward 5’- GAT-TTG-GAC-CTG-CGA-GCG-3’ 
IPDA 
RPP30 Rv





















4.4  Droplet Generation 
The droplet generation was started with the “GAG/ENV/Hypermut” plate. The 
samples were mixed by pipetting up and down 3 times. Then 20µL of master 
mix and DNA mixture was transferred to middle row of wells of the cartridge for 
droplet generation. The wells were checked for bubbles. All bubbles were burst 
carefully using the micropipette tip. Next, the Bio-Rad droplet generation oil was 
pipetted up and down once to wet the pipette tip and 70µL of droplet generation 
oil (Bio-Rad; #186-3005), was dispensed from the solution basin (VWR; # 613-
1175) to bottom wells of cartridge. If any wells were not used in a column, the 
empty wells were filled with 20µL of 1X buffer control (1:1 supermix and water). 
A generator gasket (Bio-Rad; #186-3009) was hooked on to cartridge holder. 
The QX200 droplet generator was opened and the adaptor containing the 
cartridge and gasket was placed into the unit for droplet generation.  
Next, a multichannel pipette was positioned at ~30-45° angle into the topmost 
wells of the DG8 cartridge (droplet generator cartridge; Bio-Rad; #186-4008), 
which contained the freshly generated droplets. Approximately 44µL from the 
droplet wells was drawn into the pipette tips and then slowly dispensed into the 
appropriate column of 96-Well semi-skirted PCR plate based on plate layout on 
the “IPDA Analysis Template.” This process was repeated for all samples and 
controls in the “GAG/ENV/Hypermut” and RPP30” plates as needed. Once the 
plate was fully loaded, the plate containing generated droplets was placed onto 
the sealing stand of the PX1 PCR plate sealer instrument. 59,60,145.  
  




4.5  PCR reaction and Plate Reader 
The sealed plate was placed in the 96-well Bio-Rad C1000 Touch thermocycler. 
The thermocycler was set for 50% ramping speed (2°C/sec) and 1050C heated 
lid. The chemistry of droplets requires a lower ramping speed to achieve the 
temperature required for the PCR properly172 and the following program was 
run: 
 
The plate sat in the thermal cycler overnight. Following the completion of PCR, 
the template on the Quantasoft software of the reader was prepared using the 
following settings: 
 















RED Rare detection event
Channel 1 FAM GAG/RPP30 Shear Unknown
Channel 2 HEX ENV/RPP30/Unknown
ddPCR Super-Mix (no dUTP)




4.6  Analysis 
The results of the IPDA were analyzed using the Quantasoft Software version 
1.7.4.0917 by Bio-Rad Industries. The first step involved determining the 
number of droplets generated in each reaction well. The baseline level 
accepted was 6000 droplets which was determined empirically from prior 
experiments done in the laboratory. Any well that had less than 6000 droplets 
was labelled as “EXCLUDE” to eliminate it from analysis as this indicated that 
there was a problem with the droplet generation. Next, the 2D amplitude plot 
was opened and each set of wells was analyzed to set a threshold for the 
fluorescence. The threshold of fluorescence is set by looking at the droplet 
separation of positive and negative droplets in the controls.  
The 2D amplitude shows the droplets for the two sets of multiplex PCRs. The 
fluorophore for each multiplex PCR is different therefore, the fluorescence data 
is observed in two channels. Each quadrant shows a different DNA species. On 
the left topside, Q1 shows the channel 1 positive droplets only (3’ deleted and 
hypermutated), the right topside, Q2 shows droplets positive for both channel 
1 and channel 2 (intact), the left bottom Q3 shows negative droplets and the 
right bottom Q4 shows the droplets positive for channel 2 only (5’ deleted) as 
seen in Figure 4. 
Due to different florescence characteristics, GAG-ENV-Hypermut and RPP30 
Shear/RPP30 have different threshold settings. The data were saved in a csv 
format for the calculations to determine the intact, 3’ defective/hypermutated, 5’ 
defective and total HIV-1 DNA copies/ million PBMCS. 




   
The calculations were done using the formula:  
Concentration = − ln (
𝑁𝑛𝑒𝑔
𝑁
) ÷ 𝑉𝑑𝑟𝑜𝑝𝑙𝑒𝑡 
where Vdroplet = volume of a droplet which is 0.85nL, Nneg = the number of 
negative droplets and N = total number of droplets. This formula is given by Bio-
Rad Industries to calculate the concentration of HIV-1 DNA species. The 
formulae based on this were used for the calculations as follows:  
Concentration of gag/µL (G):  
                                − ln (1 − ((






Concentration of env/µL (E): 
−ln (1 − ((







Figure 4. 2D amplitude in Bio-Rad Quantasoft showing droplets. 
The 2D amplitude of the IPDA data shows the droplets positive for each PCR 
reaction in different quadrants. Q1 shows droplets that are positive for GAG 
amplicon only; Q2 shows droplets that are positive for both GAG and ENV 
amplicons; Q3 shows droplets that are negative for both GAG and ENV amplicons; 
Q4 shows droplets that are positive for the ENV amplicon only.  
 
 




Intact copies/µL (I) =  







5’ defective HIV- 1 DNA copies/µL (D5) = 
−ln (1 − ((
(𝑁𝑄4)
(𝑁𝑄1 +  𝑁𝑄3 +  𝑁𝑄4)




3’ defective/hypermutated HIV- 1 DNA copies/µL (D3) = 
−ln (1 − ((
(𝑁𝑄1)
(𝑁𝑄1 +  𝑁𝑄3 + 𝑁𝑄4)




where: NQ2 = number of double positive droplets; NQ1 = number of single 
positive droplets for 3’  defective; NQ3 = number of negative droplets; NQ4 = 
number of single positive droplets for 5’ defective; and Vdroplet = volume of each 
droplet i.e., 0.85nL 
For copies/well, the copies/µL was multiplied by 20 since that was the volume 
of the samples used for droplet generation.  
In a cell, it is expected that the viral genome would unsheared, but when cells 
are processed through DNA isolation and ddPCR, shearing of the genomic 
DNA occurs which can lead to underestimation of the number of intact 
proviruses. The shearing occurs due to mechanical stresses such as freeze 
thaw cycles and the passage of DNA through silicon columns in the DNA 
isolation protocol. This can be accounted for in the final calculations by using 
the housekeeping gene RPP30. The primers and probes for RPP30 and RPP30 
shear bind at a distance of 7kb on the RPP30 gene therefore if this gene shows 




shearing it is expected that the HIV-1 genome between psi (upstream of gag) 
and env is also sheared and to the same extent. The DNA shearing was 
calculated as follows: 
Concentration of RPP301/µL (R1) =  
−ln (1 − ((
(𝑁𝑄2 +  𝑁𝑄1 )
(𝑁𝑄1 + 𝑁𝑄2 +  𝑁𝑄3 +  𝑁𝑄4)




Concentration of RPP302/µL (R2) = 
−ln (1 − ((
(𝑁𝑄2 +  𝑁𝑄4 )
(𝑁𝑄1 + 𝑁𝑄2 +  𝑁𝑄3 +  𝑁𝑄4)





%unsheared (S) = 𝑁𝑄2 ÷ ( (
𝑁𝑄1+ 𝑁𝑄4
2
) + 𝑁𝑄2  ) 
where: NQ2 = number of double positive droplets; NQ1 = number of single 
positive droplets for RPP30 shear; NQ3 = number of negative droplets; NQ4 = 
number of single positive droplets for RPP30 and Vdroplet = volume of each 
droplet, i.e., 0.85nL 
Since RPP30 is diluted by a factor of 100, to calculate undiluted cells the 
following formula was used: 
Undiluted cells/µL (U) = 𝑆 ÷ ((
𝑅1+ 𝑅2
2
) × 100) 
where S = %unsheared; R1 = concentration of RPP301; R2 = concentration of 
RPP302. 
 




For undiluted cells/well, the cells/µL was multiplied by 20 since that was the 
volume of the samples used for droplet generation.  
Total cells analyzed (T) = 𝑈 ÷  (𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑤𝑒𝑙𝑙𝑠 𝑡ℎ𝑎𝑡 𝑝𝑎𝑠𝑠𝑒𝑑 𝑎𝑛𝑎𝑙𝑦𝑠𝑖𝑠 𝑝𝑒𝑟 𝑠𝑎𝑚𝑝𝑙𝑒) 
where U = Undiluted cells/µL. 
To adjust for shearing: 
Copies/shear adjusted well for each DNA species = (𝑐𝑜𝑝𝑖𝑒𝑠/𝑤𝑒𝑙𝑙)  ÷  (𝑆) 
where S= %unsheared.  
Copies/shear adjusted cells for each DNA species = 
(𝑐𝑜𝑝𝑖𝑒𝑠/𝑠ℎ𝑒𝑎𝑟 𝑎𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑤𝑒𝑙𝑙) ÷ (𝑈)  
where U = Undiluted cells/µL. 
Copies/106 cells shear adjusted for each DNA species =  
(𝑐𝑜𝑝𝑖𝑒𝑠/𝑠ℎ𝑒𝑎𝑟 𝑎𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 × 1000000) 
Total DNA = ( 𝑖𝑛𝑡𝑎𝑐𝑡 𝑐𝑝𝑚 + 3′𝑑𝑒𝑙 𝑐𝑝𝑚 + 5′𝑑𝑒𝑙 𝑐𝑝𝑚 ) 
where cpm = copies/million shear adjusted cells 
 
5. Whole Genome Amplification and Primer Sequencing 
Whole genome amplification (WGA) was performed using the Qiagen REPLI-g  
single cell kit (#150343; Qiagen, Valencia, California) on samples that did not 
show any result in the IPDA. It was suspected that these samples had primer-
probe mismatches171. Since DNA was limited, this approach was used to 
ensure favorable outcomes.   




5.1 Whole Genome Amplification 
The buffer DLB was reconstituted per the manufacturer’s instructions. Buffers 
D1 and N1 were prepared for 8 samples using the following table: 
 
The master mix was prepared using the following table, but polymerase was 
not added at this stage.  
 
2.5µL of template DNA was added to each of the wells in a fresh 0.2mL 24 well 
PCR plate followed by the addition of 2.5µL of Buffer D1. The plate was 
vortexed and spun at 1000 rpm for 15 seconds followed by incubation at room 
temperature for 3 minutes. The plate was kept on ice, and 5µL of Buffer N1 was 
added to the wells. The content of the wells was mixed by pipetting up and 
down. The polymerase was added to the master mix as per the table. The 
Master mix tube was then vortexed and spun briefly. 40µL of this Master Mix 
was then added to each of the wells (containing 10µL of denatured DNA) while 
the plate was still on ice. The plate was vortexed, spun at 1000 rpm for 15 
seconds and placed in the thermocycler.  
 
Table 3 (A): Buffer preparation for Whole Genome Amplification  
Component Buffer D1 x9 Buffer N1 x9
Reconstituted Buffer DLB 63µL -
Stop Solution - 81µL
Nuclease Free Water 225µL 459µL
 
Table 3 (B): Preparation of Master Mix for Whole Genome Amplification 
 
Component Volume (µL)
Nuclease Free Water sc 61
REPLI-g sc reaction Buffer 261
REPLI-g sc DNA polymerase 18
Total Volume 340




The following program was run: 
 
5.2 PCR for Psi and Env regions 
To start sequencing, the WGA products had to undergo two PCR reactions that 





















u5gagSGS_fo forward 5' GTARCTAGAGATCCCTCAGAC 3'
u5gagSGS_ro reverse 3' TGACATGCTGTCATCATYTCYTC 5'
u5gagSGS_fn forward 5' AAATCTCTAGCAGTGGCGCC 3'
u5gagSGS_rn reverse 3' CATCATTTCTTCTARTGTAGCTSCT 5'
envSGS_fo forward 5' GCCAGTAGTRTCAACYGAA 3'
envSGS_ro reverse 3' GCARATGAGTTTCTYAGAGCA 5'
envSGS_fn forward 5' CTGCTAAATGGCAGTCTAGC 3'











The next day, the Master Mix for the outer PCR was prepared using the table 
below:
 
2µL of the WGA product was taken and added to a fresh 0.2mL 24 well PCR 
plate. 8µL of the Master Mix for Outer PCR was added. The plate was vortexed, 
spun at 1000 rpm for 15 seconds and placed in the thermocycler171. The 
following program was run: 
 
After this the outer PCR product was taken and 10µL of Tris-HCl 10mM was 
added to it to dilute the outer PCR product for a nested PCR. The Master Mix 


















10x PCR buffer 
(Invitrogen; #P/N 52045)
2.5 22.5
50mM MgCl2 (Invitrogen; 
# P/N52044)
1 9
10mM PCR Nucleotide 
mix (Promega; #U151B)
0.5 4.5
50µM Forward primer 
Outer
0.5 4.5
50µM Reverse primer 
Outer
0.5 4.5
5U/µL Platinum Taq 
(Invitrogen; #11304-011)
0.2 1.8
Nuclease Free Water 19.8 178.2
Total Vol 25 225
Template Vol 1 9





2µL of the diluted outer PCR product was taken and added to a fresh 0.2mL 24 
well PCR plate. 18µL of the Master Mix for Nested PCR was added. The plate 
was vortexed, spun at 1000 rpm for 15 seconds and the following program was 
run: 
 
The PCR product was run on a gel to determine the correct band size. If the 
band was of the appropriate size, the product was tip purified and sent for 
Sanger Sequencing171; else, the sample was kept aside for the near full-length 



















10x PCR buffer 
(Invitrogen; #P/N 52045)
2.5 22.5
50mM MgCl2 (Invitrogen; 
# P/N52044)
1 9
10mM PCR Nucleotide 
mix (Promega; #U151B)
0.5 4.5
50µM Forward primer 
Nested
0.5 4.5
50µM Reverse primer 
Nested
0.5 4.5
5U/µL Platinum Taq 
(Invitrogen; #11304-011)
0.2 1.8
Nuclease Free Water 19.8 178.2
Total Vol 25 225
Template Vol 1 9




5.3 Four fragment PCR and Alternative env PCR 
The primer sets for each fragment are listed in Table 6. 
 
For the samples that did not show bands in the Gels for the nested u5gag and 
env PCR, a near full-length four fragment PCR was run. The outer PCR master 
mix was prepared using the table below: 
 
1.67µL of template DNA from the samples (except sample 3 at W208, there 
was not enough DNA, so the WGA product was taken), was added to a fresh 
 
Table 6: Primers for the near-full length Four fragment PCR 
A 275F/3 In Out
B 263 F/ 3 AccOut
C 5 In out/BLInnerR
D 5 AccOut/280R
Fragment Primer set (Forward/Reverse)
 
Table 7: Preparation of Master Mix for Four fragment outer PCR 






BLouterF Primer (10 
µM) 
BLouterR Primer  (10 
µM)  
LongAmp Hot Start 
Taq DNA Polymerase
1 6 6
H2O 14.58 6 87.48










0.2mL 24 well PCR plate and followed by 23.33µL master mix. The plate was 
vortexed, spun at 1000 rpm for 15 seconds and the following program was run:  
 
The next day, the outer PCR product was diluted 1:3 by adding 50 µL of 
Nuclease free water to the wells. The plate was vortexed and spun at 1000 rpm 
for 15 seconds.  
































3.34µL of template DNA from the samples, was added to a fresh 0.2mL 24 well 
PCR plate and followed by 46.66 µL master mix. The plate was vortexed, spun 
at 1000 rpm for 15 seconds and the following program was run: 
 
Table 8: Preparation of Master Mix for Four fragment inner PCR 
5X LongAmp Buffer 10 5 50
Reverse primer  (10 uM) 2 5 10
Template DNA 3.34
TOTAL 46.66 233.3




dNTP (10 uM) 1.5 5 7.5
Volume per RXN (µL) Master Mix (µL)
Forward primer (10 uM) 2 5 10
LongAmp Hot Start  Taq 2 5 10
For Fragment C & D + alternative ENV primers, 6 rxns were prepared





*the time varied based on primers for each fragment. The 68oC step for outer 
PCR for Fragment A & D was run for 5 min and for Fragment B & C it was run 
for 6 min 30 seconds. 
The PCR product was run on a gel to determine correct band size. If it matched, 
the product was tip purified and sent for Sanger Sequencing171.  
 
6. HIV-1 Parameters and Characteristics for the PHACS-AMP Cohort  
In the current study, remnant genomic DNA samples from a prior study on the 
Adolescent Master Protocol (AMP), the Pediatric HIV AIDS Cohort Study 































was used for samples from the PHACS-AMP cohort to study HIV-1 reservoir 
dynamics in perinatal infections60. PHACS is a longitudinal study based in the 
United States to understand the long-term outcomes of perinatal HIV-1 
infections210. In PHACS, over 451 children/adolescents living with perinatal 
HIV-1 infection were enrolled of which 61 were eligible for the previous study 
based on virologic control and number of available samples60. The study 
reported here was further limited based on having sufficient available genomic 
DNA, and detectable levels of HIV-1 DNA upon testing using the POL-LTR 
ddPCR assay60,145. Since the present study was going to be run on remnant 
samples from previous studies done on the same cohort in the lab60, a few 
criteria were used to determine which samples were to be tested. The criteria 
were as follows:  
• The remnant sample needed to have a minimum of 2000ng of DNA to allow 
for sufficient input genomic DNA60. 
• Samples needed to have 2LTR circles ≤ 10 copies/million PBMCs, to be in 
the more steady state levels of reservoirs on effective ART.  
• The participant should have been on effective ART with undetectable 
plasma viral loads in clinical assays, i.e., achieved virologic suppression (as 
defined below).  
Virologic suppression was defined as plasma viral load (pVL) ≤400 copies/mL 
for the duration of the study while permitting single pVL≥400 copies/mL in 
between measurements of pVL≤400 copies/mL59,60.  Of the 61 participants in 
the previous study, 25 matched these criteria. Their HIV parameters and 
characteristics are presented in table 9.   








<1 year old 
(N=8) 
1 to 5 years old 
(N=17) 
Sex 
 M 10 (40%) 3 (38%) 7 (41%) 
 F 15 (60%) 5 (63%) 10 (59%) 
Year of birth 
 Mean 
(SD) 
1997 (3) 1998 (1) 1997 (3) 
 Median 1997 1998 1996 
 Q1, Q3 1995, 1999 1997, 2000 1994, 1999 
HIV prophylaxis$ 
 Yes 5 (20%) 2 (25%) 3 (18%) 
 No 20 (80%) 6 (75%) 14 (82%) 
Number of pre-cART# ART regimens 
 Mean 
(SD) 
0.76 (1.09) 0.13 (0.35) 1.06 (1.20) 
 Median 0 0 1 
 Q1, Q3 0, 1 0, 0 0, 2 
Duration of pre-cART# ART regimens (years) 
 Mean 
(SD) 
0.77 (1.25) 0.00 (0.01) 1.13 (1.38) 
 Median 0.00 0.00 0.42 
 Q1, Q3 0.00, 1.19 0.00, 0.00 0.00, 1.66 
Type of cART+ 
 PI alone 18 (72%) 5 (63%) 13 (76%) 
 PI + 
NNRTI 
4 (16%) 1 (13%) 3 (18%) 
 NNRTI 
alone 
3 (12%) 2 (25%) 1 (6%) 
Age at cART+ initiation (years) 
 Mean 
(SD) 
1.73 (1.70) 0.24 (0.11) 2.44 (1.64) 
 Median 1.13 0.24 2.23 
 Q1, Q3 0.25, 3.33 0.15, 0.28 1.13, 3.60 
Age at cART+ initiation (months) 
 Mean 
(SD) 
20.80 (20.42) 2.87 (1.30) 29.25 (19.70) 








<1 year old 
(N=8) 
1 to 5 years old 
(N=17) 
 Median 13.60 2.89 26.81 
 Q1, Q3 2.96, 40.01 1.77, 3.38 13.60, 43.20 
HIV RNA (log10 c/mL) at cART+ initiation 
 Mean 
(SD) 
4.82 (0.87) 4.76 (1.36) 4.85 (0.50) 
 Median 4.90 5.23 4.83 
 Q1, Q3 4.30, 5.43 3.54, 5.82 4.38, 5.35 
 Missing 2 0 2 
CD4% at cART+ initiation 
 Mean 
(SD) 
30 (11) 37 (9) 26 (10) 
 Median 30 33 28 
 Q1, Q3 25, 39 31, 42 23, 33 
 Missing 2 0 2 
Age at confirmed virologic suppression* (years) 
 Mean 
(SD) 
2.5 (1.7) 0.66 (0.2) 3.4 (1.4) 
 Median 2.2 0.66 3.7 
 Q1, Q3 0.90, 3.8 0.46, 0.86 2.2, 4.7 
Age at confirmed virologic suppression* (months) 
 Mean 
(SD) 
30.3 (21.2) 7.9 (2.5) 41.6 (16.9) 
 Median 26.9 7.9 44.3 
 Q1, Q3 10.7, 45.9 5.4, 10.2 26.9, 56.9 
Years from cART initiation to confirmed virologic suppression* 
 Mean 
(SD) 
0.84 (1.0) 0.42 (0.1) 1.0 (1.2) 
 Median 0.44 0.36 0.46 
 Q1, Q3 0.32, 0.59 0.30, 0.57 0.33, 1.3 
Months from cART initiation to confirmed virologic suppression* 
 Mean 
(SD) 
10.0 (12.7) 5.0 (2.1) 12.3 (14.9) 
 Median 5.2 4.3 5.5 
 Q1, Q3 3.8, 7.1 3.5, 6.9 3.9, 15.8 








<1 year old 
(N=8) 
1 to 5 years old 
(N=17) 
Age (years) at first specimen 
 Mean 
(SD) 
5.0 (2.5) 3.3 (2.5) 5.8 (2.2) 
 Median 5.1 3.8 6.3 
 Q1, Q3 3.2, 7.3 0.86, 4.5 4.4, 7.4 
Age (years) at last specimen 
 Mean 
(SD) 
8.0 (2.3) 6.8 (1.8) 8.5 (2.4) 
 Median 7.8 6.7 8.7 
 Q1, Q3 6.3, 9.7 5.4, 8.4 7.3, 10.6 
 
Table 9: HIV parameters and characteristics, by age at virologic suppression 
#pre-cART involves the administration of ARV prophylaxis 
+cART = combination antiretroviral therapy 
*confirmed virologic suppression is defined as plasma viral load (pVL) ≤400 copies/mL59,60 
 
7. Statistical Analysis 
Optimizing the assay:  
The intact HIV-1 DNA copies/million PBMCs for each amount of DNA input 
were run against the JLAT standards on an XY plot followed by analysis using 
simple linear regression in GraphPad Prism v8.4.3. The %unsheared data sets 
were analyzed using non-parametric independent t-tests (Mann-Whitney) and 
with significance defined as α = 0.05.  
For the purposes of this study, the limit of detection (LOD) was calculated using 
the number of cells analyzed and therefore varied between samples. For each 
DNA input, the LOD of the dataset was determined by the lowest copy number 
of HIV-1 DNA concentration that was detectable in >95% of the runs.   




Applying the assay to participant samples:  
The intact, 5’deleted, 3’deleted/hypermutated and total HIV-1 DNA 
copies/million PBMCs were analyzed using box plots, and non-parametric 
unpaired Mann Whitney t-tests were used to compare runs between the four 
HIV-1 DNA species with significance defined as α = 0.05.  The DNA species 
were analyzed as mentioned above for both age at virologic suppression and 
duration of virologic suppression. As the laboratory members were blinded to 
the distribution of samples by age at virologic suppression, the PHACS 
statisticians performed the analysis for age at virologic suppression using the 
descriptive statistics function in SAS v9.4. The p-values for this stratification 
were not calculated owing to the small size of the cohort.  
The rest of the analysis was done by the author of the thesis using GraphPad 
Prism v8.4.3. The number of cells analyzed per participant/time point and the 
% unsheared per participant/time point were plotted and non-parametric 
unpaired Mann Whitney t-tests were run with significance defined as α = 0.05. 
The % intact for each time point was calculated by dividing the intact 
copies/million PBMCs by the total copies/million PBMCs, and non-parametric 
unpaired Mann Whitney t-tests were run between the three sub-groups of 
duration of virologic suppression with significance defined α = 0.05. The p-
values might be affected by the size of the cohort, number of time points per 
participant and limit of detection for each sample based on the input number of 
cells analyzed. The total DNA copies/million PBMCs obtained from the POL-
LTR and IPDA assays were compared, and a non-parametric Spearman 
correlation was performed. The same was repeated for each species detected 




by IPDA vs the total DNA from the POL-LTR assays. The t-tests were unpaired 
as not every sample had paired values for all time points. The medians and the 
interquartile range for all the data were calculated using the descriptive 
statistics function in GraphPad Prism v8.4.3 and SAS v9.4.  
  






1.  Optimizing the Intact Proviral DNA Assay (IPDA) 
 
1.1 . Establishing  controls for the IPDA. 
Cell lines were tested as controls. JLATs were used as they contain one copy 
of integrated HIV-1 DNA per cell, which is thought to be the case for HIV-1 
infection226. The JLATs were tested using 1000 ng input of genomic DNA per 
well in eight replicates to maximize detection at low copy numbers of HIV-1 
DNA. As shown in Figure 5A, linearity was observed at higher concentrations, 
and down to 25 HIV-1 DNA copies/million PBMCs between the expected and 
observed intact HIV-1 DNA from the JLAT cells for all three DNA input amounts. 
This showed that the dilution series worked well with the assay at 
concentrations >25 copies/million PBMCs. At 10 HIV-1 DNA copies/million 
PBMCs, we started losing linearity, and precision and the variation was 
increasing perhaps owing to Poisson statistics. This implied that to gain more 
precision at and below 10 HIV-1 DNA copies/million PBMCs, more experiments 
needed to be run with higher number of replicates.  
Based on the results, it was concluded that JLAT cells performed well in terms 
of linearity and quantification compared to the expected HIV-1 DNA 
copies/million PBMCs. When studying a wide range of proviral loads, JLAT cells 
can inform about assay characteristics over this range and could be used to 




further define the assay characteristics in lower range of HIV-1 proviral DNA 
copies detected in paediatric samples.  
1.2 . Sensitivity of IPDA 
The next step was to determine the minimal DNA input at which  the assay can 
successfully detect intact HIV-1 DNA copies using different input genomic DNA, 
since it may not always be possible to have sufficient DNA in the samples to 
input 1000ng in eight replicates. Therefore, the chosen input genomic DNA 
amounts were added at 500ng and 200ng. As seen in Figure 5B and C, there 
was good linearity between the expected and observed intact HIV-1 DNA 
copies/million PBMCs at these lower inputs of genomic DNA down to 25 HIV-1 
DNA copies/million PBMCs. For 1000ng, the assay could not reliably detect 
intact copies below a concentration of 5 intact HIV-1 DNA copies/million 
PBMCs, suggesting a limit of detection of 5 intact HIV-1 DNA copies/million 
PBMCs. With 200ng and 500ng DNA input, the detection was not reliable below 
5 intact copies/million PBMCs. 
For 500ng, 10 intact HIV-1 DNA copies/million PBMCs were detected 100% of 
the time, and 5 and 2.5 intact HIV-1 DNA copies/million PBMCs were detected 
75% of the time. For 200ng, 10 intact HIV-1 DNA copies/million PBMCs were 
detected 100% of the time, and 5 and 2.5 intact HIV-1 DNA copies/million 
PBMCs were detected 25% of the time. 
 






Figure 5. Intact HIV-1 DNA copies/million with different input DNA amounts. 
A: Three runs were performed with 1000ng DNA from JLAT+ PBMC standard (two 
different blood bags).  B: Four independent runs were performed with DNA isolated 
from JLAT+ PBMC standards, normalized to a concentration of 500ng (two different 
blood bags). C. Four independent runs were performed with genomic DNA isolated 
from JLAT+ PBMC standards, normalized to a concentration of 200 ng (one blood 
bag). 
Each run is represented in a different color. Linear regression for all the data points 
in at the three DNA input concentrations was performed. The linear regression can 
be observed with the solid line. The open symbols indicate samples in which HIV-
1 DNA was not detected by the assay. These samples were set to their respective 
limit of detection values, which vary with the number of cells analyzed. The dotted 
line indicates the LOD of the assay for each DNA input. Blood bags were obtained 
from the New York Blood Center and processed as described in methods. Runs 
2,3 of 1000 ng and 3,4 of 200 ng had only 3 data points corresponding to I1,I2,I3. 
Some data points are superimposed in figure 5B & C; however, the number of runs 
is as stated earlier. 




The IPDA was developed for adult samples, where the median proviral load is 
between 10-100 HIV-1 DNA copies/million PBMCs69. Pediatric patients on early 
long-term suppressive ART tend to have proviral loads <20 HIV-1 DNA 
copies/million PBMCs59,60,196,199. The poor reliability and high variation of the 
assay below 10 HIV-1 DNA copies/million PBMCs makes it better suited for late 
suppression than early suppression. However, testing with more replicates may 
help improve the sensitivity of the assay.  
Following testing with different amounts of input DNA, the number of cells 
analyzed, and the percentage of shearing were the next characteristics that had 
to be determined. The number of cells analyzed is affected by the number of 
replicates (wells) and the total amount of DNA input per well. If the amount of 
DNA input is higher or the number of replicates is higher or both, more cells will 
be analyzed. It was observed that for 8000ng input DNA for a sample (1000ng 
in 8 replicates), a median of 697,827 cells were analyzed, while for 4000ng 
(500ng in 8 replicates) input DNA, a median of 462,810 cells were analyzed, 
and for 1600ng (200ng in 8 replicates) input DNA, a median of 135,418 cells 
were analyzed (Data not shown). 
Shearing is most heavily affected by the DNA isolation step of the IPDA owing 
to mechanical stresses, freeze thaw cycles and the silicon column used for 
isolation. For the standards, the Qiagen Qi-Amp Midi kit was used to isolate 
DNA and then the IPDA was run. It was noted that the percent unsheared was 
highly variable and ranged from 35-75%, with the majority of samples lying in 
between 50-70% (Figure 6). The median for the 85 data points analyzed was 
62% unsheared, with the interquartile range of 57.3%- 64.4%.  




Although the %unsheared was similar to the previously published range as 
reported69, it was important to minimize shearing as much as possible since 
pediatric participant samples can have exceedingly low concentrations of HIV-
1 DNA and therefore low % unsheared could cause the assay to miss the intact 
provirus in the participants. 
 
 
1.3 . Impact of method of DNA isolation on Shearing 
Paediatric samples have low proviral loads59,60,196,199. Therefore, we strived to 
achieve as high a %unsheared as possible and since reducing shearing is high 
priority, we tested out a different method of isolation using the Qiagen Gentra 
 
Figure 6. Range of  % Unsheared observed over a series of runs. 
The range of % unsheared HIV-1 DNA observed over different experiments, was 
mostly concentrated between 50 – 70% using the Qiagen Qi-AMP Blood DNA Midi 
kit. The median was 61.6% for n=85 samples. The interquartile range (IQR) was 
57.3% - 64.4%.  




Puregene Blood kit (Cat # 158467). As seen in Figure 7, the % unsheared on 
average was higher for Qiagen Gentra Puregene Blood kit compared to the 
Qiagen Qi-Amp Blood DNA Midi kit, and the difference was statistically 
significant, p<0.0001. Over three performers, lower shearing was observed 
using the Gentra Puregene protocol vs the Qi-amp that was performed by one 
person.  Analysis of the other samples isolated using the Qiagen Qi-Amp kit by 
other performers in our laboratory have shown higher shearing percentages 
(data not shown).   
The Qiagen Gentra Puregene Blood kit performed better since it does not 
include columns, which can enhance the shearing of DNA. Hence, Qiagen 
Gentra Puregene Blood kit is better suited for isolating genomic DNA for assays 
that require higher concentration of unsheared DNA, like the IPDA. However, 
this was not possible for the PHACS samples used in this study as the DNA 
was previously isolated for another study60 using the Qiagen Qi-AMP Blood 
DNA Midi Kit (Cat #51183).  
 
2. Applying the IPDA to PHACS samples 
Next, the IPDA was applied to study the reservoir dynamics in participant 
samples from a previous study in which we observed differences in proviral 
DNA decay as a function of age at virologic suppression60. However, the 
prior study was limited by the single-plex HIV-1 DNA assay used to measure 
total proviral reservoir size because that assay did not distinguish intact from 
defective proviruses. 






2.1 Participant characteristics 
As mentioned earlier, in this study, DNA samples from the previous study on 
the PHACS-AMP cohort were used. 25 participants matched the criteria for the 
current study mentioned earlier. Of the 25 participants, 8 had achieved virologic 
suppression (VS) before 1 year of age (median = 0.66 years), while 17 had 
achieved virologic suppression between 1-5 years of age (median = 3.4 years), 
 
Figure 7. % Unsheared observed from DNA isolated using two different 
methods and kits. 
The different colors represent DNA isolated from different technicians. The green 
symbols indicate DNA isolated by Performer 1, purple symbols indicate DNA 
isolated by Performer 2 and the black symbols indicate DNA isolated by Performer 
3.  
 




as seen in Table 9. The median age at confirmed VS was 7.9 months for the 
group that achieved VS<1 year of age (group 1) and 44.3 months for those that 
achieved VS between 1-5 years of age (group 2).  The ratio of females to males 
studied was 3:2 for the entire cohort (Table 9).  
Out of the 25 participants, 1 had six time points available for study, 4 had five, 
5 had four, 3 had three, 7 had two and 5 had one, for a total of 74 time points 
available for study. However, owing to our selection criteria mentioned in the 
methods, time points that had 2LTR ≥ 10 ( 5 time points) and purported primer- 
probe mismatch issues (7 time points) were excluded from the analysis. One 
participant had a time point which had to be eliminated due to extremely low 
droplet formation in the IPDA.  Hence of the original 74 time points, only 61 
were used for analysis.  
2.2  Performance characteristics of the IPDA on PHACS-AMP 
Some of the most important performance characteristics that need to be 
analyzed for the IPDA are the % unsheared and the number of cells analyzed, 
as these affect the conclusions that can be derived from the assay. The % 
unsheared for this study set (Figure 8) ranged between 40 – 55% with a median 
of 46%, which is lower than that observed for the standards (Figure 6) that 
ranged primarily between 50 - 70% with a median of 61.6%. Since the study 
used samples whose DNA was isolated 5 years ago, tested multiple times and 
underwent several rounds of freeze thawing, relatively low % unsheared was 
expected. 
  






With respect to the number of cells analyzed, this ranged from 100,000 to 
360,000 cells, with a median of 232,384 cells and with most of the samples 
lying between 200,000 - 270,000 (Figure 9A). The cells analyzed/well ranged 
from 15,000 - 45,000 cells/well with a median of 29,048 cells analyzed/well, and 
with most lying between 25,000 - 35,000 cells/well (Figure 9 B). Another metric 
to gain insight into the number of cells analyzed is cells analyzed/well. The 
number of total cells analyzed is affected by the number of wells excluded from 
analysis i.e., with more wells analyzed, the total number of cells will increase 
 
Figure 8.  % Unsheared for the cohort. 
The range of % unsheared observed over different samples was mostly 
concentrated between 40 – 55%. The % unsheared contains data from participants 
at most times points. Samples with 2LTR values ≥10 and participants with 
purported primer-probe binding issues are excluded. N= 61, Median %unsheared  
= 46, Interquartile range (IQR) = 42 – 50. The DNA for these samples was isolated 
over 5 years ago and has been tested several times and underwent various 
mechanical stresses which affect the shearing.  
 




and vice versa. Generally, the expected range of cells analyzed for 200ng DNA 
input in 8 replicates is between 250,000 - 300,000 cells. But to study and fully 
characterize the reservoir more cells along the lines of 800,000 - 1,000,000 
should be analyzed.  
2.3 Data Analysis by Stratification 
For this study, the data were stratified by two factors: age at virologic 
suppression (VS) and duration of virologic suppression. Based on these factors, 
two and three subgroups were defined as follows: 
Age at virologic suppression: <1 year (21 timepoints on 8 participants); 1-5 
years (40 timepoints on 17 participants) 
Duration of virologic suppression: <2 years (22 timepoints), 2-5 years (34 
timepoints), >5 years (6 timepoints) 
 







Figure 9. Total cells analyzed and cells analyzed/well for the cohort. 
Panel A: Total cells analyzed. The total cells analyzed were mostly concentrated 
between 200000 – 270000. Total cells analyzed: N= 61, Median = 232384, 
Interquartile range (IQR) = 198531  – 268241 
Panel B: Cells analyzed per well. The cells analyzed/well were mostly concentrated 
between 25000 - 35000. Samples with 2LTR values ≥10 and participants with 
purported primer-probe binding issues were excluded. The total cells analyzed by 
the assay are impacted by the replicate wells. Cells analyzed/well: N= 61, Median 
= 29048, Interquartile range (IQR) = 24816 – 33530. 





Overall, intact HIV-1 proviruses were detected in 33/61 samples (54.1%) tested 
on the 25 participants (8 with VS<1 year of age and 17 with VS between 1-5 
years of age) studied with an input concentration of 200 ng in 8 replicates and 
a median of 232,384 cells analyzed (IQR 198,531 - 268,241). The median 
concentration of intact HIV-1 proviruses detected was 11.1 copies per million 
PBMCs (range 4.5 - 57.7 copies/million PBMCs). When stratified by age at 
virologic suppression (VS), it was observed that group 1 (age at VS<1) had 
fewer detectable intact HIV-1 DNA copies/million PBMCs (3/21) than group 2 
(age at VS between 1-5) which had 30/40 intact proviruses detectable.  
 
Figure 10. Distribution of PBMC-associated intact HIV-1 DNA. 
The plot is based on age at virologic suppression. Samples with 2LTR values ≥10 
and participants with purported primer-probe binding issues were excluded. The 
open symbols indicate samples in which HIV-1 DNA was not detected by the assay. 
Assay results below limit of detection were set to their respective detection limits 








When stratified by duration of virologic suppression, it was observed that the 
intact HIV-1 DNA declined with increasing duration of suppression.  
The intact HIV-1 proviral copies (Figure 10), for the participants who achieved 
VS before 1 year of age, were lower (Median = 4.6 intact HIV-1 DNA 
copies/million PBMCs) compared to those who achieved VS between 1-5 years 
of age (Median = 18.8 intact HIV-1 DNA copies/million PBMCs); however, it 
was important to note that the median of 4.6 HIV-1 DNA copies/million PBMCs 
for the early suppressed group was not precise since it lay amongst the pool of 
undetectable proviral loads while the median for the later suppressed group 
was definitive. For the values that were undetectable, we assigned them the 
limit of detection of each sample, which were the highest values we could have 
assigned. Therefore, the median HIV-1 DNA copies/million PBMCs was at most 
4.6 for the early suppressed group. Our conservative approach ensured that 
any significant change we noted with the current analysis would add more 
confidence that it is a real observable change.  





Similar trends were seen for 5’ deleted HIV-1 proviruses copies (Figure 11) and 
3’ deleted/hypermutated HIV-1 proviruses (Figure 12) with medians of 22 and 
36.9 5’deleted HIV-1 DNA copies/million PBMCs, and 16.1 and 66.1 3’ 
deleted/hypermutated HIV-1 DNA copies/million PBMCs for age at VS<1 and 
age at VS between 1-5 years, respectively.  
 
Figure 11. Distribution of PBMC-associated 5'-deleted (defective) HIV-1 DNA. 
The plot is based on age at virologic suppression. Samples with 2LTR values ≥10 
and participants with purported primer-probe binding issues were excluded. The 
open symbols indicate samples in which HIV-1 DNA was not detected by the 
assay. Assay results below limit of detection were set to their respective detection 
limits which vary with the number of cells analyzed. IQR = Interquartile range 
 





Since the total DNA is the sum of intact and defective HIV-1  DNA copies/million 
PBMCs, this trend was also observed for total copies HIV-1  DNA copies/million 
PBMCs with medians of 32.2 and 178.9 total HIV-1 DNA copies/million PBMCs 
for the respective age groups (Figure 13).  
The data for the intact HIV-1  DNA copies/millions PBMCs for those who 
achieved VS<1 year of age could have been potentially affected by the lower 
number of time points (21) in this group compared to the other group (VS 1-5 
years of age) which had almost 2X more time points (40). Therefore, by 
analyzing more time points and increasing the amount of DNA input, it may be 
 
Figure 12. Distribution of PBMC-associated 3'-deleted/hypermutated 
(defective) HIV-1 DNA. 
The plot is based on age at virologic suppression. Samples with 2LTR values ≥10 
and participants with purported primer-probe binding issues were excluded. The 
open symbols indicate samples in which HIV-1 DNA was not detected by the assay. 
Assay results below limit of detection were set to their respective detection limits 
which vary with the number of cells analyzed. IQR = Interquartile range 
 
 




possible to get a better idea of the distribution of intact proviruses in the group 
that achieved VS<1 year of age.  
  
To understand the trends better and determine if the HIV-1 DNA copies/million 
PBMCs decayed over time for each group of age at VS, the first and last time 
points were further analyzed.  
The intact HIV-1 DNA copies/million PBMCs seemed to have decreased 
between the first (Figure 14 A) and last (Figure 14 B) time points for the group 
that achieved VS<1 year of age with medians of 4.9 and 4.6 intact HIV-1 DNA 
copies/million PBMCs, respectively. The intact HIV-1 DNA copies/million 
PBMCs for the group that achieved VS between 1-5 years of age also seemed 
 
Figure 13. Distribution of PBMC-associated total (intact and defective) HIV-1 
DNA. 
The plot is based on age at virologic suppression. Samples with 2LTR values ≥10 
and participants with purported primer-probe binding issues were excluded. The 
open symbols indicate samples in which HIV-1 DNA was not detected by the assay. 
Assay results below limit of detection were set to their respective detection limits 
which vary with the number of cells analyzed. IQR = Interquartile range 
 
 




to have decreased between the first (Figure 14 A) and last time (Figure 14 B) 
points with medians of 57.7 and 11.2 intact HIV-1 DNA copies/million PBMCs. 
However, this trend was not observed for the defective and total (defective + 
intact) HIV-1 DNA copies/million PBMCs.  
In the case of 5’ deleted HIV-1 DNA copies/million PBMCs, there was an 
increase between the first (Figure 15 A) and last (Figure 15 B) time points for 
both the groups of age at VS with medians of 6.3 and 33.9 (Age at VS<1) and 
30.3 and 37.2 (Age at VS 1- 5 years) HIV-1 DNA copies/million PBMCs, 
respectively.  
For the 3’ deleted/hypermutated HIV-1 DNA copies/million PBMCs, there was 
an increase between the first (Figure 16 A) and last (Figure 16 B) time points 
for both the groups of age at VS with medians of 10.5 and 20.8 (Age at VS<1) 
and 44.6 and 87.1 (Age at VS 1- 5 years) HIV-1 DNA copies/million PBMCs, 
respectively.  
Consequently, the total HIV-1 DNA copies/million PBMCs, increased in 
between the first (Figure 17 A) and last (Figure 17 B) time points for the group 
that achieved VS < 1 year  of age  with medians of 18.8 and 57.2 respectively. 
There was a decrease of total HIV-1 DNA copies/million PBMCs between first 
(Figure 17 A) and last (Figure 17 B) time points for the group that achieved VS 
between 1-5 years with medians of 193.0 and 178.9 HIV-1 DNA copies/million 
PBMCs, respectively.  
 
 







Figure 14. Distribution of PBMC-associated intact HIV-1 DNA, by age at 
virologic suppression (first and last chronologic sample per participant). 
Panel A: Data for first chronological point and Panel B: Data for last chronological 
point. The plot is based on age at virologic suppression at the first and last 
chronological samples collection. Certain participants did not have 2 time points 
therefore may not be accurately depicted here. Samples with 2LTR values ≥10 and 
participants with purported primer-probe binding issues were excluded. The open 
symbols indicate samples in which HIV-1 DNA was not detected by the assay. 
Assay results below limit of detection were set to their respective detection limits 
which vary with the number of cells analyzed. IQR = Interquartile range 
 
 






Figure 15. Distribution of PBMC- associated 5'-deleted (defective) HIV-1 DNA, 
by age at virologic suppression (first and last chronologic sample per 
participant). 
Panel A: Data for first chronological point and Panel B: Data for last chronological 
point. The plot is based on age at virologic suppression at the first and last 
chronological samples collection. Certain participants did not have 2 time points 
therefore may not be accurately depicted here. Samples with 2LTR values ≥10 and 
participants with purported primer-probe binding issues were excluded. The open 
symbols indicate samples in which HIV-1 DNA was not detected by the assay. 
Assay results below limit of detection were set to their respective detection limits 
which vary with the number of cells analyzed. IQR = Interquartile range 
 




Next, the data was stratified and analyzed by duration of virologic suppression 
(VS) and was divided into three groups <2 years of VS (22), 2-5 years of VS 
(34), >5 years of VS (6).  
When stratified by the duration of VS, the distributions of the different species 
followed different trends with increasing duration of virologic suppression. The 
intact HIV-1 DNA demonstrated a decline between each group of duration of 
VS with medians of 41.2 (VS<2 years), 8.3 (VS=2-5 years) and 4.9 (VS>5 
years) intact HIV-1 DNA copies/million PBMCs (Figure 18 A). The decline in 
intact HIV-1 DNA copies/million PMBCs between VS<2 years and VS 2- 5 years 
was statistically significant with a  p value of 0.0012 (α = 0.05). The decline 
between intact HIV -1 DNA copies/million PMBCs between VS<2 years and 
VS>5 years was statistically significant with a  p value of 0.0236 (α = 0.05) while 
the decline between VS 2-5 years and VS>5 years was not statistically 
significant.  
A similar trend was also noted for 5’ deleted HIV-1 DNA copies/million PBMCs 
(Figure 18 D). The total and 3’ deleted/hypermutated HIV-1 DNA copies/million 
PBMCs showed an initial decline followed by an increase in their concentrations 
(Figure 18 B and C).  
The total HIV-1 DNA copies/million PBMCs declined between the VS<2 years 
and VS for 2-5 years with medians of 138.5 and 61.5 HIV-1 DNA copies/million 
PBMCs, respectively. Then an increase was noted between VS for 2-5 years 
and VS>5 years with medians of 61.5 and 93.9 HIV-1 DNA copies/million 
PBMCs, respectively (Figure 18 B). The changes amongst the three subgroups 




of duration of virologic suppression for total HIV-1 DNA were not statistically 
significant. 
The 3’ deleted/hypermutated HIV-1 DNA copies/million PBMCs showed an 
initial decline from VS<2 years to VS = 2-5 years with medians of 57.4 and 29.4 
HIV-1 DNA copies/million PBMCs, respectively. This was followed by an 
increase in 3’ deleted/hypermutated HIV-1 DNA copies/million PBMCs between 
VS for 2-5 years and VS> 5 years with medians of 29.4 and 61.2 HIV-1 DNA 
copies/million PBMCs, respectively (Figure 18 C). The changes in 
3’deleted/hypermutated proviruses amongst the three subgroups of duration of 
virologic suppression were also not statistically significant.  
The 5’ deleted HIV-1 DNA copies/million PBMCs showed a relatively slow 
decline with increasing duration of suppression with medians of 35.5 (VS<2 
years), 29.4 (VS = 2-5 years) and 26.8 (VS>5 years) HIV-1 DNA copies/million 
PBMCs (Figure 18 D). The changes in 5’deleted copies/million PMBCs 
amongst the three subgroups of duration of virologic suppression were not 
statistically significant.  
 
 
Table 10: Medians of  HIV-1 DNA species segregated based on duration of 
virologic suppression.  

















less than 2 years 41.2 35.5 57.4 138.5
2 - 5 years 8.3 29.4 29.4 61.5
greater than 5 years 4.9 26.8 61.8 93.9




When the proportion of total HIV-1 DNA that is intact was analyzed between 
the three groups of duration of VS, a decline in the proportion of intact HIV-1 
DNA with increasing duration of VS was noted (Figure 19). However, not every 
participant had a sample for each group and therefore these results could 
potentially be skewed by this as well as the small cohort size.  
The %intact values that were at or above 100% were a result of the total (sum 
of intact + 3’ deleted/hypermutated + 5’ deleted HIV-1 DNA copies/million 
PBMCs) HIV-1 DNA copies/million PMBCs being equal to or less than the intact 
HIV-1 DNA copies/million PMBCs. This can be attributed to the poor/lack of 
detection of 3’ deleted/hypermutated or 5’ deleted or both 5’ deleted and 3’ 
deleted/hypermutated HIV-1 DNA copies/million PBMCs.  
The IPDA was designed to quantify intact proviruses when the reservoir is 
stable, and the proportion of intact proviruses is not very high. However, in the 
current study, it could be possible that the time points analysed were around 
the time that the reservoir was still stabilizing and had not recached the second 
stage of the biphasic decay leading to the presence of many copies of intact 
proviruses. As a result of this the quantification by the IPDA might have become 
less accurate.  
 
 






Figure 16. Distribution of PBMC-associated 3'-deleted/hypermutated 
(defective) HIV-1 DNA, by age at virologic suppression (first and last 
chronologic sample per participant). 
Panel A: Data for first chronological point and Panel B: Data for last chronological 
point. The plot is based on age at virologic suppression at the first and last 
chronological samples collection. Certain participants did not have 2 time points 
therefore may not be accurately depicted here. Samples with 2LTR values ≥10 and 
participants with purported primer-probe binding issues were excluded. The open 
symbols indicate samples in which HIV-1 DNA was not detected by the assay. 
Assay results below limit of detection were set to their respective detection limits 
which vary with the number of cells analyzed. IQR = Interquartile range 
 







Figure 17. Distribution of PBMC- associated total (intact + defective) HIV-1 
DNA, by age at virologic suppression (first and last chronologic sample per 
participant). 
Panel A: Data for first chronological point and Panel B: Data for last chronological 
point. The plot is based on age at virologic suppression at the first and last 
chronological samples collection. Certain participants did not have 2 time points 
therefore may not be accurately depicted here. Samples with 2LTR values ≥10 and 
participants with purported primer-probe binding issues were excluded. The open 
symbols indicate samples in which HIV-1 DNA was not detected by the assay. 
Assay results below limit of detection were set to their respective detection limits 
which vary with the number of cells analyzed. IQR = Interquartile range 
 







Figure 18.  Distribution of various HIV-1 DNA species as a function of duration 
of Virologic Suppression. 
Panel A: Intact HIV-1 DNA copies/million PBMCs as a function of duration of 
suppression. Panel B: Total (intact + defective) HIV-1 DNA copies/million PBMCs 
as a function of duration of suppression. Panel C: 5’ deleted (defective) HIV-1 DNA 
copies/million PBMCs as a function of duration of suppression. Panel D: 3’ 
deleted/hypermutated (defective) HIV-1 DNA copies/million PBMCs as a function 
of duration of suppression. Samples with 2LTR values ≥10 and participants with 
purported primer-probe binding issues were excluded. The dotted lines depict the 
average limit of detection for the cohort. The open symbols indicate samples in 
which HIV-1 DNA was not detected by the assay. Assay results below limit of 
detection were set to their respective detection limits which vary with the number 










Figure 19. Proportion of total HIV-1 DNA that was intact.  
Panel A: % Intact HIV-1 DNA as a function of duration of suppression. Panel B: 
Total (intact + defective) HIV-1 DNA copies/million PBMCs as a function of duration 
of suppression Samples with 2LTR values ≥10 and participants with purported 
primer-probe binding issues were excluded. The dotted lines depict the average 
limit of detection for the cohort. The open symbols indicate samples in which HIV-
1 DNA was not detected. Assay results below limit of detection were set to their 
respective detection limits which vary with the number of cells analyzed. The red 
dots depict data points where the intact was greater than the total. There was an 
outlier, a time point where the %intact was 13155 and was excluded from the 
graph. However, this outlier did not impact the median values.  IQR = Interquartile 
range. CPM = Copies/Million 




2.4 Individual Data 
Based on the individual plots (Supplementary figures 1-5) the reservoir 
dynamics for each participant were quite variable. However, most data (14/25) 
could be grouped based on similar trends. The three major trends observed 
were: variable total HIV-1 DNA copies/million PBMCs (CPM PBMCs) over time 
(supplementary figure 1), declining HIV-1 DNA CPM PBMCs over time 
(supplementary figure 2) and stable HIV-1 DNA CPM PBMCs over time 
(supplementary figure 3). The total HIV-1 DNA CPM PBMCs is a measure of 
the sum of intact HIV-1 DNA copies/million PBMCs, 3’ deleted/hypermutated 
HIV-1 DNA copies/million PBMCs and 5’deleted HIV-1 DNA copies/million 
PBMCs. Therefore, changes in any of these three species would be reflected 
in the total HIV-1 DNA CPM PBMCs.  In the participants (6/25) that 
demonstrated variable total HIV-1 DNA CPM PBMCs over time, it was observed 
that the total HIV-1 DNA was in a state of constant flux with an increase followed 
by decrease in the HIV-1 intact and defective species or vice versa. The 
participants (4/25) that demonstrated declining total HIV-1 DNA CPM PBMCs 
over time had declining concentrations of all species which is what one would 
expect with increasing time on ART and duration of VS.  
With respect to stable HIV-1 DNA CPM PBMCs (4/25), it was noted that the 
proportion of the intact to defective (3’ deleted/hypermutated or 5’ deleted) HIV-
1 DNA copies/million PBMCs was such that if a decline were observed in one 
species, a proportional change would be observed in the other two species to 
compensate for the change in intact proviruses. In this case, a decline in the 
intact HIV-1 DNA CPM PBMCs was compensated by changes in the 




proportions of the 3’ deleted/hypermutated and 5’ deleted HIV-1 DNA CPM 
PBMCs.  
The remaining participants (11/25) were stratified into three groups: those that 
only had one time point (4/25, Supplementary figure 4), those that needed 
further testing (5/25, Supplementary figure 5) and those that had purported 
primer-probe binding issues (2/25). For the group with only one time point no 
major conclusions could be derived from their data. The two participants of the 
25 that demonstrated what appeared to be primer-probe binding issues were 
tested further to confirm this171.  
 
3. IPDA vs Pol LTR on PHACS samples 
As the IPDA is a relatively new ddPCR assay that is used for studying the HIV- 
1 reservoir, it was interesting to see how its results would correlate with those 
of  previous assays used for studying the HIV-1 reservoir. Since there was data 
from POL-LTR assay (previous study) used to study the reservoir on the 
PHACS cohort60, correlations were run between the data from the POL-LTR 
assay and the IPDA. The POL-LTR assay gave a measure of the total HIV-1 
DNA copies/million PBMCs vs the IPDA which gave a measure of total, intact, 
3’ deleted/hypermutated and 5’ deleted HIV-1 DNA copies/million PBMCs. For 
each of these species a non-parametric Spearman’s rank test was performed 
to note the correlation and a unpaired t-test was performed to determine the p-
value with α = 0.05.  




The total HIV-1 DNA copies/million PBMCs from the IPDA when compared to 
the total HIV-1 DNA copies/million PBMCs from the POL-LTR assay showed a 
positive Spearman’s correlation co-efficient (r) = 0.8259 , p<0.0001 (Figure 20 
A). When the intact HIV-1 DNA copies/million PBMCs were compared with the 
total HIV-1 DNA copies/million PBMCs from the POL LTR assay, a positive 
correlation was noted with r = 0.6981 and p<0.0001 (Figure 20 B). The 5’ 
deleted (Figure 20 C) and 3’ deleted/hypermutated (Figure 20 D) HIV-1 DNA 
copies/million PBMCs when compared with the total HIV-1 DNA copies/million 
PBMCs from the POL-LTR assay, also showed a positive correlation; however, 
they had lower r values (compared to intact HIV-1 DNA species) of 0.6779 and 
0.6186, p<0.0001, respectively.  
 
4. Determination of primer-probe mismatch 
During analysis, a 2D plot shows each species in a different XY quadrant based 
on the PCR reaction and the fluorophore. Quadrant 1 shows the 3’ deleted and 
hypermutated proviruses, quadrant 2 shows intact HIV-1 proviruses, quadrant 
3 shows some proviruses that did not amplify at both regions + negative 
reactions for HIV-1 DNA and quadrant 4 shows 5’ deleted proviruses. (Figure 
4). If the primer/probe is unable to bind to its respective region in the gag/env 
portion of the HIV-1 genome, fluorescence will not be observed in that DNA 
species’ quadrant as well as quadrant 2. This would indicate a primer-probe 
binding issue as was observed for two participants171.  
 







Figure 20. Correlations between Total HIV-1 DNA Copies/Million PBMCs 
detected by POL-LTR assay vs HIV-1 DNA Copies/Million PBMCs of all 
species by IPDA. 
Panel A: Total HIV-1 DNA Copies/Million PBMCs (IPDA) vs Total HIV-1 DNA 
Copies/Million PBMCs (POL) Panel B: Intact HIV-1 DNA Copies/Million PBMCs vs 
Total HIV-1 DNA Copies/Million PBMCs (POL) Panel C: 5’ deleted HIV-1 DNA 
Copies/Million PBMCs vs Total HIV-1 DNA Copies/Million PBMCs (POL) Panel D: 
3’ deleted/hypermutated HIV-1 DNA Copies/Million PBMCs vs Total HIV-1 DNA 
Copies/Million PBMCs (POL). Samples with 2LTR values ≥10 and participants with 
purported primer-probe binding issues were excluded. The open symbols indicate 
samples in which HIV-1 DNA was not detected by the assay. Assay results below 
limit of detection were set to their respective detection limits which vary with the 
number of cells analyzed. Non-parametric Spearman test was run on all 
correlations to determine the Spearman correlation co-efficient and two-tailed t 










The 2D amplitude plot for two participants, PHACS sample 3 and PHACS 
sample 13 did not show droplets in the quadrant for intact HIV-1 DNA (Q2) and 
env HIV-1 DNA (Q4), and intact HIV-1 DNA (Q2) and gag HIV-1 DNA (Q1), 
respectively, as seen in Figure 21. Based on a previous study by Simonetti et 
al., it appeared to be a primer-probe mismatch171. To confirm this, the samples 
were tested further. Two PCRs were performed using a set of primers that 
covered more area than that bound by the IPDA primers, and near full-length 
primers respectively. Primer-probe mismatches were confirmed for both the 
participants based on these PCR results. PHACS sample 25 which did not 
show any droplets in all three quadrants, Q1, Q2 and Q4 was also tested for 
primer-probe mismatch. 
4.1  Amplifying the primer-probe binding region 
To ensure that there was enough remnant genomic DNA for further analyses, 
whole genome amplification was performed followed by the outer and nested 
PCRs using the primers shown in Table 4. The nested PCR products were run 
on a 1% gel as seen in Figure 22. All the time points for PHACS sample 3 
showed bands for gag, two of four time points for PHACS sample 13 showed 
gag bands at the right position of 1183 bp. Only one time point of PHACS 
sample 13 showed a band for env at 957 bp. PHACS sample 25 did not show 
any amplicons and was not tested further. On repeating the nested PCR with a 
1:10 diluted outer PCR product, the env PCR for PHACS sample 3 still failed to 
show amplicon bands after the gel electrophoresis as did the u5gag PCR for 
the last two time points for PHACS sample13 (Figure 23).  








Figure 21. Primer-Probe mismatch in participant samples. 
Panel A: 2D amplitude plot showing potential primer probe mismatch for ENV 
region Panel B: 2D amplitude plot for controls of the same run. Panel C: 2D 
amplitude plot showing potential primer probe mismatch for u5GAG region Panel 
D: 2D amplitude plot for controls of the same run. The lack of droplets in Q3 + Q2 
and Q1 + Q3 respectively indicate that there may be a primer-probe mismatch 
involved. 






Based on these results, we thought that there may have been a mismatch even 
with the sequencing primers. Therefore, a near full-length four fragment PCR 
was performed to help amplify the proviruses that could not be amplified using 
the sequencing primers in Table 4. Gel electrophoresis was performed on the 
nested 4 fragment PCR products (Figure 24). PHACS sample 13 did not show 
amplicons for Fragment A or B (Figure 3). PHACS sample 3 showed amplicons 
for Fragment C and D (Figure 3) at 6385bp and 4778bp respectively, as well as 
the alternative env primers at 2841bp. This confirmed that there was a primer-
probe mismatch for PHACS sample 3.  
 
 
Figure 22. Gel Electrophoresis of Nested PCR for u5gag and env regions. 
Lane 1: Ladder, Lane 2-4: u5GAG PS3, Lane 5-8:u5GAG PS13, Lane 9-10:u5GAG 
PS25, Lane 12-14: ENV PS3, Lane 15-18:ENV PS13, Lane19: ENV PS25 
In the nested u5GAG PCR, all the time points for PS3 had a band for gag as 
expected. The first 2 time point for PS13 showed amplicon bands at the correct size 
of 1183bp while the other two time points had no band and a light band at the wrong 
size respectively. PS 25 did not show an amplicon band for u5GAG. 
In the nested Env PCR, most of the time points except one time point in PS 13 did 
not show an amplicon band. The PS 13 env amplicon was at the correct size of 957 








As for PHACS sample 13, the two time points that showed gag amplicons in 
the first set of PCRs (using the sequencing primers in table 4) were sent for 
Sanger sequencing while it was believed that the last two time points either had 





Figure 23. Gel Electrophoresis of Repeated Nested PCR for u5gag and env 
regions.  
Lane 1: Ladder, Lane 2-3: u5GAG PS13, Lane 4: control, Lane 6-8: Env PS3, Lane 
9; control, Lane 12-14: ENV PS3, Lane 15-18:ENV PS13, Lane19: ENV PS25 
The nested env PCR was repeated with a 1:10 dilution for all time points of PS3 
and the u5gag nested PCR was repeated with a 1:10 dilution for 2 time points of 
PS13. Based on the gel, it was noted that the env PCR had failed while PS13 
timepoints failed to show u5gag. PS= PHACS sample 
 






4.2.  Sanger sequencing 
Sanger sequencing was performed on PHACS sample 3 and PHACS sample 
13 using the nested primer shown in Table 4. The sequences were then aligned 
with the reference HXB2 and the primer-probe of each set. For PHACS sample 
3, it was noted that there was a primer mismatch (forward primer) as well as a 
probe mismatch which led to the lack of detection of the env region by the IPDA. 
In the forward primer mismatch (Figure 25 A), within the highlighted region, a 
consistent single nucleotide change from G to A was observed for all time 
points. For PHACS sample 3 W78 another G to A change was observed in the 
primer binding region. The probe mismatch (Figure 25 B) showed three single 
 
Figure 24. Near full-length four fragment PCR Gel Electrophoresis. 
Lane 1-2 Fragment A, Lane 3 Fragment A control; Lane 4-5 Fragment B, Lane 6: 
Fragment B control Lane 7: Ladder; Lane 8-10 Fragment C; Lane 11 Fragment C 
control; Lane 12-14 Fragment D, Lane 15 control; Lane 16 Ladder; Lane 17-19 
Alternative env primers; Lane 20 Control for env primers.  
 
All PS3 samples showed a positive band for Fragment C at 6385 bp although the 
band in lane 8 was truncated; Fragment D at 4778 bp and the ENV primers at 
2841bp. PS13 bands were not observed for Fragment A and Fragment B at the 
appropriate band size. PS: PHACS sample 




nucleotide polymorphisms of pyrimidine to purine changes, with two C to G and 
one C to A mutation within the highlighted region. 
 
For PHACS sample 13, two time points were sequenced and while there was 
no primer mismatch, it was noted that there was a probe mismatch which led 
to lack of detection of the gag region by the IPDA (Figure 26). In the case of 
PHACS sample 13, only the forward primer sequences could be aligned as the 
probe bound closer to that region and the reverse primer amplicon was not long 
enough to reach the probe binding region.  
 
Figure 25. Sanger Sequencing and alignment results for env region 
mismatch. 
Panel A: Sequence alignment of forward and reverse amplicons vs HXB2 genome 
as a reference and the env forward primer. The highlighted region depicts the 
primer binding region. All the sample sequences showed a single nucleotide 
polymorphism at the same site G to A. The sample at time point W78 had another 
mismatch with a G to A mutation.  
Panel B: Sequence alignment of forward and reverse amplicons vs HXB2 genome 
as a reference and the env probe. The highlighted region depicts the probe binding 
region. All the samples showed three single nucleotide polymorphisms of 
pyrimidine to purine with two C to G and one C to A mutation.  
 





The next step will be to get the individual primer probes developed for each of 
the participants and the IPDA will be re-run.  
  
 
Figure 26. Sanger Sequencing and alignment results for u5gag region 
mismatch. 
The sequence of the forward amplicon was aligned against the HXB2 genome as 
a reference and the probe of the u5GAG. Two mismatches close to the 5’ end of 
the probe binding region seemed to have contributed to primer-probe mismatch. 
Reverse amplicon is not depicted as it did not cover the probe binding region. No 
mismatches were seen in the primer binding regions. Sample sequences were 
consistent across the 2 time points tested. 
 






Optimization of the IPDA 
To optimize the Intact Proviral DNA Assay (IPDA), it was crucial to determine: 
a) the best control for the assay; and b) the performance characteristics of the 
assay. The JLAT cell line was chosen to develop controls as previously 
published data have shown that JLAT cells have only one copy of integrated 
HIV-1 DNA per cell and are stable over many passages225. Plasmids were not 
used as a control because the plasmid vials contain very concentrated plasmid 
levels (high copy number) which can result in cross contamination with controls 
for other assays in the laboratory. Additionally, the JLAT cells were preferred 
over the use of plasmids, as the JLAT cells have an integrated copy of HIV-1 
DNA which mimics the reservoir as seen in-vivo224. Thus, JLAT cells were 
chosen to develop controls for the IPDA. 
Once the controls were developed, the performance characteristics were 
determined. The IPDA was run using different amounts of DNA input. The 
genomic DNA used for the assay was isolated from the JLAT standards with 
varying concentrations of proviral DNA copies/million PBMCs. The amounts of 
DNA input were 1000ng, 500ng and 200ng. The assay was able to detect HIV-
1 DNA copies for all three DNA input amounts (1000ng, 500ng, 200ng). 
Regardless of the amount of input DNA, the expected vs observed HIV-1 DNA 
copies/million PBMCs fell within the acceptable range (± 10% error).  




The linearity was maintained for all three input DNA amounts which was very 
important and proved that the dilution scheme worked for all three amounts of 
DNA input.  
In the case of 1000ng DNA input, the assay could not reliably detect intact HIV- 
1 DNA copies below a concentration of 2.5 intact HIV-1 DNA copies/million 
PBMCs. For the 500ng and 200ng DNA input, the assay detection was less 
predictable with some runs showing detection below 5 intact HIV-1 DNA 
copies/million PBMCs. This suggests that: 1) the assay is unable to reliably 
detect below 10 HIV-1 DNA copies/million PBMCs; and 2) the assay has a limit 
of detection between 5 - 2.5 intact HIV-1 DNA copies/million depending on the 
amount of genomic DNA input. Similar limits of detection were observed in the 
Siliciano laboratory, where the assay was developed69.  
An important point to note is that perinatally infected children (early suppressed) 
have low proviral loads, usually below 25 HIV-1 DNA copies/million PBMCs as 
seen later with PHACS samples, therefore it is important for the IPDA to reliably 
detect HIV-1 DNA below 10 HIV-1 DNA copies/million PBMCs. One of the 
reasons that could explain why the detection becomes more variable below 10 
HIV-1 DNA copies/million PBMCs is that the IPDA was developed for use 
during chronic treatment. It has been noted that hypermutations and deletions 
rates may be different in early treated participants, which could affect the 
performance of the IPDA168.  
Based on current observations, the assay may not be well suited as a 
standalone assay for detecting proviral loads in early suppressed participants; 
however, it is well suited for studying the reservoir in later suppressed 




participants. As mentioned earlier, this issue may potentially be resolved by 
running experiments with a greater number of replicates.   
As stated before, the maintenance of linearity is important when the assay is 
applied to participant samples that may not have sufficient DNA to input 1000ng 
per well for multiple replicates. Knowing that the assay worked well even at 
lower input DNA amounts allows the assay to be applied to samples regardless 
of DNA input to study the reservoir, albeit with limitations for samples containing 
lower than five intact proviruses. 
The next sets of performance characteristics that affected the readout of the 
assay were shearing of DNA and number of cells analyzed. Based on the limit 
of detection of the ddPCR assays optimized in our laboratory, it was empirically 
determined that to get a good estimate of the composition of the reservoir, i.e., 
the intact proviruses that can re-establish viremia when ART is stopped, ideally 
800,000 to 1,000,000 cellular equivalents (from PBMCs or CD4 T cells) of 
genomic DNA should be analyzed.  But it is not always possible to analyze 1 
million cellular equivalents, as it requires genomic DNA extraction from 3-5 
million PBMCs.  
In pediatric HIV-1 infections studying the reservoir is complex and challenging 
not only due to the evolving immunology from neonates to young adults or 
routes of transmission but also owing to blood sampling. Neonates can be 
infected by an HIV-1 positive mother either in-utero or during the intra-partum 
period (perinatal infection) or through breast feeding10. If the infection is left 
untreated the neonate dies within 1-3 years of birth7, to prevent this, ART is 
started as soon as the infection is diagnosed, which can be anywhere between 




1-3 months of birth or if the neonate is at high risk for infection, within 
days/weeks of birth3,92,227,228. The consequences of this early treatment are very 
low proviral loads7,216.  
With respect to blood sampling, based on the weight of the neonate, about 2.5-
5mL of blood can be drawn from a neonate. This volume increases as the 
weight of the infant increases but is usually not more than 50mL in 
adolescents229-231. The low volumes make it difficult to extract 5 million cells for 
analysis of the reservoir in perinatal infections and the output from processing 
the blood sample has to be maximized. In some cases, less than 5 million cells 
are obtained. During optimization of the IPDA in the present study, standards 
with 3 million cells were used to determine if the assay would function 
appropriately. The number of cells analyzed fell between 150,000 - 350,000 
which made it challenging to study the proviral reservoir; however even though 
the number of cells were not ideal, we were still able to study the reservoir. This 
proved that although cells analyzed are an important factor, in an unideal 
situation where the pellet size is less than 5 million cells, the reservoir can still 
be studied to inform ART-free remission strategies, and the number of cells 
analyzed need not be a strong limiting factor.  
The shearing index of DNA is extremely important in the IPDA. DNA is 
unsheared in a cell but when it is processed for isolation and ddPCR, the DNA 
breaks into fragments. This shearing, if not accounted for results in an 
underestimation of the number of intact HIV-1 DNA copies present in the 
sample, and the size of the reservoir. Hence it is important to account for 
shearing accurately and it is done by using the housekeeping gene RNase P30 




as described earlier69. Accounting for shearing is especially important in 
pediatric HIV-1 infections owing to early treatment resulting in low proviral 
loads. Therefore, it is very important to minimize shearing from the first step of 
processing the cells i.e., DNA isolation, which we can improve in future studies 
with use of the non-column-based approaches for genomic DNA extraction from 
cells.  
We showed that when the Qiagen Qi-Amp kit was used for the isolation of 
genomic DNA from the standards, a median %unsheared of 61.62% was 
obtained. This meant that about 39% of the DNA had been fragmented. This 
rate of shearing can be attributed to mechanical stresses, freeze thaw cycles 
and to the passing of DNA through the silica column used in the Qiagen Qi-amp 
Midi kit. Upon isolating the DNA using the Qiagen Gentra Puregene core B kit, 
the median of %unsheared was 75.55%. This could be because the Gentra 
Puregene kit reduces the mechanical stresses, minimizes vortexing and 
eliminates the use of silicon columns. The Gentra Puregene kit was tested by 
three different performers and we saw similar findings of reduced shearing. 
Hence the comparison between the two kits used for isolation demonstrated 
that the lack of columns can affect the %unsheared.  
However, when the IPDA was established by Bruner et al., it was noted that the 
Qiagen Qi-amp kit was used for isolation of genomic DNA (samples from adults) 
and the shearing was accounted for using the RNase P30 gene PCR only and 
not at the step of DNA isolation69. This was less impactful on the results 
because the adult participants had very high levels of intact proviruses (a 




median of 100 intact HIV- 1 DNA copies/million CD4 T cells), which was not the 
case for pediatrics as observed upon applying the IPDA to the PHACS samples.  
When the IPDA was applied to the PHACS cohort study, the shearing of the 
DNA was quite high with the majority of samples falling within 45-60% sheared 
DNA. This was expected as these samples had been processed and isolated 
over five years60. The DNA underwent several freeze thaw cycles, and other 
mechanical stresses as different assays were performed on this sample set.  
The observable impact of this shearing may have influenced the lack of 
detection of intact HIV-1 proviruses in the cohort with only 54.1% of the 61 
samples showing detectable intact HIV-1 DNA copies/million PBMCs. As 
mentioned earlier, the low detection of intact HIV-1 DNA copies would be 
expected with such high shearing levels since proviral loads in children are very 
low. Therefore, when applying an assay like the IPDA to study the reservoir 
size and dynamics, it is best to minimize shearing from step 1 (i.e., DNA 
isolation) and to process a fresh aliquot of the samples when possible, to avoid 
underestimating the reservoir size.  
The Gentra Puregene kit reduces the amount of shearing at the step of DNA 
isolation, which reduces the need to rely on shear correction done post ddPCR, 
while analyzing the samples. This is important because if the DNA has a very 
low %unsheared as seen for PHACS sample 10 at one time point (data not 
shown), the shear correction overcompensates and biases the results towards 
intact HIV-1 DNA copies which can affect the results of the study. However, this 
does not imply that using the Qi-amp kit instead of the Gentra Puregene kit is 
not acceptable, since we can still study the reservoir.  




It just means that in pediatric infections, it is preferred to account for shearing 
from step 1 which can be done by using a kit like the Gentra Puregene.  
 
Applying the IPDA to children living with perinatal HIV-1 in the PHACS-
AMP cohort 
In the past studies on perinatal HIV-1 infections across different cohorts, 
durations of suppression and subtypes of HIV-1, it was observed that the 
reservoir size decreased with early treatment and suppression vs deferred 
treatment or late suppression55,59,191,196,199,201-203,207,215,216,220,222.  
However, the reason for decrease in the size of the reservoir was not well 
elucidated hence to understand what was going on, in a seminal study, Uprety 
et al., studied the decay dynamics of the reservoir in long-term suppressed 
children from the Pediatric HIV AIDS Cohort Study60. They observed that within 
the first two years of virologic suppression (VS), the HIV-1 DNA decayed much 
faster in early suppressed group than it did in the later suppressed group60. This 
explained the reason for the smaller reservoir sizes in early treated children but 
the exact reason for the decay of total HIV-1 DNA was not clear. Therefore, to 
further elucidate the differential rate of decay, IPDA was performed on the 
PHACS group.  
The Pediatric HIV AIDS cohort study, Adolescent Master Protocol is a long- 
term longitudinal study of children and adolescents living with perinatal HIV-1 
in the U.S.210 As mentioned earlier in the previous studies done on the PHACS 
cohort, the investigators were able to ascertain that early treatment reduced the 




proviral size. The previous study done in our laboratory by Uprety et al., used 
the banked samples from this cohort to study the decay dynamics of the proviral 
DNA based on age at virologic suppression (VS) in order to understand the low 
proviral loads seen in children who achieved virologic control from infancy60.  
The previous study utilized a single-plex ddPCR, total HIV-1 DNA assay: POL-
LTR to measure proviral loads over years of virologic suppression and noted 
the differences between the group that achieved virologic suppression early (<1 
year of age; group 1) vs the group that achieved virologic suppression late ( >1 
year of age; group 2)60. An important observation was that on stratifying the 
data by age at virologic suppression, the decay rates for the proviral reservoir 
were different based on the age at virologic suppression. For the group 1 (VS<1 
year), the rate of decay was much faster with vs  group 2 (VS 1-5 years) with 
rates of -0.50 log10 HIV-1 DNA copies/million PBMCs and -0.15 log10 HIV-1 
DNA copies/million PBMCs respectively. An inflexion point was observed at 2 
years post confirmed VS, after which the slopes were not very different between 
the two groups with decay rates of -0.03 log10 HIV-1 DNA copies/million PBMCs 
and -0.05 log10 HIV-1 DNA copies/million PBMCs respectively60. This difference 
was noted even though both groups started off with similar concentrations of 
total HIV-1 DNA at the time of confirmed virologic suppression.  
The observation of a faster decay rate of total HIV-1 DNA the group with earlier 
VS during the first 2 years of VS in the study by Uprety et al., sparked interest 
in understanding the dynamics of the reservoir and proviral species with timing 
and duration of VS60. However, as mentioned earlier, the study used a single-
plex ddPCR assay to measure the total HIV-1 DNA load. Assays that measure 




the total HIV-1 DNA overestimate the size of the reservoir as they also measure 
the defective proviruses which dominate the proviral landscape 
64,65,68,70,144,145,151,153,155,165.  
This overestimation of the reservoir size can negatively affect ART-free 
remission strategies aimed to clear the latent replication-competent reservoir, 
which is the reason for rebound of viremia when a person is taken off ART48-
53,87,88. Hence in the current study, we applied the Intact Proviral DNA Assay 
(which can differentiate between intact and defective proviruses)69, to study the 
composition of the reservoir and understand what led to a rapid decay of the 
reservoir size in early suppressed children69.  
For the current study on the PHACS cohort, we hypothesized that the group 
with early treatment and suppression ended up freezing the reservoir with a 
higher proportion of intact HIV-1 DNA (at the time of ART initiation) that would 
have potential for selective elimination compared to the cohort with later 
virologic suppression, where defective proviruses would preferentially 
accumulate and therefore be less likely to be cleared. The reason behind this 
hypothesis was late suppression, mimics untreated infection where the HIV-1 
is able to circulate long enough for the development of HIV-1 specific immune 
response57. Hence when the intact proviruses are reactivated (late 
suppression), they are rapidly cleared by the immune response and viral 
cytopathic effects giving rise to a landscape dominated by defective proviruses. 
This would potentially explain why the decay rate for the total HIV-1 DNA would 
be faster within the first two years of suppression in group 1 vs group 2.  




To test this hypothesis, samples from the PHACS-AMP cohort that were 
remnant from the previous study60 were taken and tested with the IPDA to 
understand the composition and dynamics of the reservoir. These samples also 
helped in understanding the effect of duration of the early antiretroviral therapy 
and virologic suppression on the dynamics and composition of the reservoir 
over time.  
In this study, it was noted that for some participants the total HIV-1 DNA was 
stable while the intact and defective HIV-1 DNA were in a flux. It was observed 
that a decline in intact HIV-1 DNA was compensated with increases in the 
proportions of 5’ deleted or 3’ deleted/hypermutated HIV-1 DNA.  This was a 
very interesting observation as it could have implications in terms of reservoir 
maintenance.  
What contributed or led to this proportional change in the defective HIV-1 
genomes? Could clonal amplification have played a role in the change of the 
defective HIV-1 genomes? Clonal amplification has been previously speculated 
and shown to be involved in the maintenance of the defective 
genomes57,69,111,167,176,232.  
In the current study, 8% of the participants (2/25) demonstrated primer-probe 
mismatches, 4% showed a mismatch for the env region and 4% showed a 
mismatch for the gag (psi) region respectively. The next step would be to create 
new primer-probes for these participants and run the IPDA again on these 
samples to study the reservoir.  In a study done by Simonetti et al, in 400 adults 
on effective ART, across several cohorts, 2.8% showed env signal failure and 




primer-probe mismatch while 3.5% showed gag (psi) signal failure and primer-
probe mismatch171.  
In another study by Gaebler et al., involving 39 participants on effective ART, 
18% of the participants demonstrated IPDA gag (psi) or env signal failure169. Of 
these at least 2 belonged to another clade of HIV-1 group M while the remaining 
14.7% belonged to clade B169.  
An interesting observation in the study by Gaebler et al., was that 4/39 
participants i.e., 10.3% demonstrated reduced fluorescent signaling. The 
reason behind this was a mismatch in the env probe. Therefore, two different 
types of signal reductions were observed in adults with respect to mismatches 
in the primer-probe or just the probe169. In contrast, for the current study, only 
signal failure and not low fluorescence was observed. However, due to the 
small cohort size, it is possible that low fluorescence amplitude may not have 
caused a problem as yet but may do so when the IPDA is applied to a much 
larger cohort in pediatric participants169.  
One striking observation made in our cohort was seen in the case of participant 
PHACS sample 25. PHACS sample 25 demonstrated what appeared to be a 
double signal failure in the IPDA 2D amplitude. At first, we thought that this 
might be a case of primer-probe mismatch perhaps owing to subtype 
differences. The PCR results indicated otherwise, upon two tries, no amplicon 
bands for gag (psi) or env were retrieved. The PCR had worked for other 
samples, so it appeared to an issue with the sample. However, upon checking 
the POL-LTR assay results for the particular time point for PHACS sample 25, 
it was noted that the value for POL HIV-1 DNA copies/million PBMCs was also 




undetectable. Owing to lack of sample quantity and only one time point for this 
participant, based on the IPDA and the POL-LTR assay, it was concluded that 
this participant may have had very low proviral loads that were undetectable by 
both of the assays60. Since only 200 ng of DNA was tested in 8 replicates, the 
number of cells analyzed fell between 150000 - 350000 which could have also 
led to this lack of detection of proviruses. Increasing the DNA input, and 
therefore the number of cells analyzed, may allow detection of the proviruses 
in this sample as suggested by a recent study done by Peluso et al62.   
For some participants, the intact HIV-1 DNA copies/million PBMCs did not 
stably decline over time, instead occasional fluctuations were observed. These 
samples need further analysis to understand the factors that lead to this state 
of flux. A viral blip may have occurred prior to sample collection which would 
explain the sudden increase in intact HIV- 1 DNA copies/million PBMCs in some 
cases. Another possibility could be high 2LTR circle values which are 
considered to be indicative of new infections, although this still remains a point 
of debate in the field233-235.  
A drawback of the IPDA, as mentioned earlier, is that it cannot differentiate 
between unintegrated and integrated forms of HIV-1 DNA and is not very 
accurate in measuring the reservoir during ongoing replication. Therefore, 
2LTR circle values ≥ 10 copies/million PBMCs could have impacted the results 
on the individual basis and hence those time points were eliminated from further 
analysis.  
Crude HLA-typing could also be done to determine if the sample indeed 
belonged to the respective participant. In such long-term studies, the samples 




are collected at testing sites and undergo a series of processing steps before 
they arrive at the laboratories for analysis. In addition to this, depending on the 
number of tests, the sample could be handled several times and manual errors 
could result in mislabeling which could affect downstream analysis. Therefore, 
in situations where there is doubt with respect to HIV biology, crude HLA typing 
can be a beneficial tool to confirm that there was no sample mix up. Similar 
results were observed in the study by Peluso et al., where some participants 
demonstrated either no change in the intact HIV-1 DNA CPM PBMCs over time 
on ART or demonstrated an expansion in the intact HIV- 1 DNA CPM PBMCs62. 
Next, the data were stratified based on age at virologic suppression and 
duration of virologic suppression. Based on age at virologic suppression, as 
expected, the distribution of intact HIV-1 DNA proviruses was lower in the group 
that achieved virologic suppression (VS) at less than one year of age (Group 
1) vs those that achieved virologic suppression between 1-5 years of age 
(Group 2).  A few reasons could explain why group 2 had a higher distribution 
of the intact HIV-1 DNA copies had a higher distribution in group 2: Since we 
were blinded, we could not identify if the samples measured for group 1 were 
from the time points later in the virologic suppression (greater than 2 years of 
VS). In addition to this, group 2 samples could have been from earlier time 
points (less than 2 years of VS, 2-5years of VS). Also, there were more samples 
with detectable intact HIV-1 DNA copies (30/40), double the number of time 
points were available for this group vs group 1 with 40 and 21 time points 
respectively.  




Another possibility for this result could be clonal expansion of the intact HIV-1 
proviral reservoirs in the later suppressed group. Expansion of the intact HIV-1 
genomes has been reported in adults although not at the same level as 
defective HIV-1 genomes57,166. A third possibility could be that early during the 
infection, the intact HIV-1 proviruses may have integrated into inactive genes 
which would prevent them from expressing viral proteins and therefore protect 
the virus from immune clearance. It could also be possible that with later 
suppression, the immune repertoire of the participants had a higher proportion 
of resting CD4 T cells than group 1, thereby allowing the virus to enter a more 
long-lived cell population23,65.  
The distribution of both 3’ deleted/hypermutated and 5’ deleted HIV-1 proviral 
genomes, was as expected with group 2 having a much higher concentration 
overall. The distribution of total HIV-1 DNA was also higher in the case of group 
2 as would be expected for participants that suppressed at a later age. When 
the data were analyzed based on the first and last time points, the concentration 
of  the defective (3’ deleted/hypermutated and 5’ deleted) HIV-1 proviruses in 
both the groups had increased between the first and the last time point, 
indicating that the defective genomes might have undergone clonal expansion. 
Integration site analysis needs to be performed to support this observation and 
quantify the expansion 57,69,111,167.  
The intact HIV-1 DNA copies showed similar decay profiles between the two 
groups. In group 1, the intact HIV-1 DNA copies declined between the first and 
last time point, the median intact HIV-1 DNA copies/million PBMCs for both the 
time points were 4.9 and 4.6 copies/million PBMCs. The apparent slow decline 




could be due to the poor detection of intact HIV-1 DNA copies, 1/21 at both time 
points. Another reason could be the longevity of the cells in which the intact 
HIV-1 proviral reservoir might be situated or the site of integration. In 
comparison to group 1, the intact HIV-1 DNA copies/million PBMCs for group 2 
also declined between the first and last time point. It is possible that some of 
the intact HIV-1 proviruses in group 2 got reactivated and hence were cleared 
by the immune mechanisms or viral cytopathic effects.   
Based on duration of suppression, the intact HIV-1 DNA copies/million PBMCs 
continued to decline from less than 2 years of VS to greater than 5 years of VS. 
The defective HIV-1 DNA copies/million followed similar patterns of decline 
followed by an increase as seen when the data were stratified by age at 
virologic control. The proportion of intact HIV-1 DNA that constitutes the total 
HIV- 1 DNA copies/million PBMCs declined from a median of 22.6% when the 
duration of VS<2 years to a median of 5.2% when the duration of suppression 
was greater than 5 years. The intact HIV-1 DNA demonstrated a decline 
between each group of duration of VS with medians of  41.2 (VS<2 years), 8.3 
(VS=2-5 years) and 4.9 (VS>5 years) intact HIV-1 DNA copies/million PBMCs. 
The decline in intact HIV-1 DNA copies/million PMBCs between VS<2 years 
and VS 2- 5 years, and VS<2 years and VS>5 years were statistically 
significant. Although there were several undetectable values, our conservative 
approach towards assigning those values their respective limits of detection 
(based on number of cells analyzed), ensure that the change we noted was 
definitive.  




This data further demonstrated that with increasing duration of suppression, the 
intact HIV-1 proviral reservoir is diminished, albeit slowly in some cases while 
the defective HIV-1 proviruses show expansion over time even in the case of 
early treated pediatric infections57,189. This study was able to show that the 
reservoir in pediatric cases is very dynamic. The size of the reservoir changes 
with age at VS as well as with duration of VS with the intact proviral reservoir 
being the most affected.  
As the measure of differential decay of the reservoir from the previous studies 
was based on total HIV-1 DNA, it was important to understand the dynamics 
and proportion of the different species within the reservoir with respect to this 
change59,60. The current study helped bridge this gap by demonstrating that in 
most cases, it was the intact HIV-1 proviral reservoir that was primarily 
responsible for the decline observed in the previous study. This has implications 
in terms of the time at which remission strategies to target the reservoir can be 
applied to achieve ART-free remission. 
The IPDA has been applied more broadly in cases of adult HIV-1 infections, 
where it was observed that intact proviruses decline with increasing duration of 
virologic suppression while defective proviruses are in a state of flux57,62. This 
is similar to what was observed in this study on pediatric HIV-1 infections.  
However, differences arise when developing an ART-free remission strategy. 
In adult HIV-1 Infections, in most cases, ART is initiated during chronic 
infection62,69,166,168,169,171 and even in the case of treatment during acute 
infections, the participants initiate ART at least 6 months after HIV-1 




infection56,58,61,168,183. This allows the reservoir to establish itself, give rise to 
viral diversity as the virus circulates uncontrolled till ART is initiated25. 
In comparison, in perinatal HV-1 infection, treatment can be started within hours 
to days of birth92 or 6 months post HIV-1 infection55,59,60,191,200,201,203,205,215,216 222 
which is unique to pediatrics. In non-human primates Simian Immunodeficiency 
Virus (SIV) is able to establish the reservoir within 3 days236. Although very early 
ART is unable to block reservoir establishment, it helps reduce the size of the 
reservoir by suppressing viremia early. The small size and low diversity of the 
reservoir in early treated perinatal HIV-1 infections make it suitable to develop 
and target strategies to achieve ART-free remission as compared to adults 
59,63,198.    
The current study was limited by the small cohort size, use of remnant genomic 
DNA which led to increased shearing, and lack of PBMC samples for similar 
time points across all participants. In spite of these limitations, insights were 
gained into the dynamics of the reservoir in perinatal HIV-1 Infections: 
1. Early suppression was associated with lower distribution of intact HIV-1 
proviruses implying that they may be cleared rapidly upon initiation of ART.  
2. The intact HIV-1 proviral reservoir decreased with increased duration of 
effective ART although the defective HIV-1 proviruses may not have 
followed this trajectory. 
3. Higher intact HIV-1 proviral copies in the later suppressed population could 
be due to clonal amplification or integration into inactive sites. 
4. Integration site analysis will help clarify point 3 and the role clonal 
amplification may play in the maintenance of the defective HIV-1 genomes. 




5. Perinatal HIV-1 reservoir dynamics follow similar trends to that seen in adult 
infections implying that early treatment may play a role in the trajectory of 
the reservoir size and composition, and the capacity to expand clonally.  
The results of the IPDA should be validated with another assay such as near 
full-length genome sequencing or Quantitative Quadraplex PCR (Q4PCR) to 
ensure an even more accurate description of the reservoir size. 169 
Conclusion and Future Directions 
Based on the results of this study, it is clear that early treatment and early 
suppression of HIV-1 replication in children with perinatal HIV-1 infections 
reduces the size of the intact proviral reservoir over time. However, further 
studies need to be done to answer the following questions: 
At what rate does the intact proviral reservoir decay with early suppression vs 
late suppression?57,60,62,166 How much of the intact proviral reservoir detected 
by IPDA can be induced in-vivo?151  This is important as intact proviruses that 
have been latently silenced or are not replication competent will continue to 
appear as intact in the IPDA, thereby affecting the results of potential ART-free 
remission strategies. What threshold of reduction in the size of the intact 
proviral reservoir can be used in perinatal infections to determine the 
effectiveness of an ART-free remission strategy?168 In a study on adults living 
with HIV-1, on ART, it was found that a greater than 6-fold decrease in the size 
of the replication competent proviruses was a reliable metric to determine the 
effects of the ART-free remission strategies90. Will this threshold also apply to 
the reservoir children? 




As mentioned earlier, pediatric and adult infections may follow the same 
trajectory but are different in terms of: 1) the size of the reservoir; 2) the % intact 
detectable after long-term suppression which is 1% in pediatric cases vs 2% in 
adults195; 3) and the immune repertoire which is reconstituted by naive CD4 T 
cells in children30 which dilute the replication competent reservoir. Therefore, 
studies on the reservoir need to continue in perinatal HIV-1 infections.  
This preliminary study had several limitations, therefore a larger study with 
more time points, fresh genomic DNA samples and similar time points would 
be beneficial in answering some of these questions. 
The data from the larger study could be analyzed to understand the effect of 
age at virologic suppression on the duration of the virologic suppression and 
the subsequently the size of the reservoir. Additional experiments such as 
developing specific primer probes for participants that initially demonstrated 
primer-probe mismatches could be done to probe the reservoir in those 
participants.  
Future studies in perinatal HIV-1 infections could include applying the IPDA 
across several cohorts to understand the performance characteristics of the 
assay similar to the study by Simonetti et al171. Near full-length genome 
sequencing (nFGS) or matched integration site proviral genome sequencing 
(MIP-seq) could be performed to elucidate 1) the role of clonal expansion in 
maintenance of the reservoir in perinatal HIV-1 infections and 2) the preferential 
sites of integration for intact proviruses in perinatal HIV-1 infections to 
understand the potential for reactivation of replication-competent 
proviruses174,177.  




Studies on the DNA methylation pattern could also be done to understand 
whether a provirus classified as intact is capable of reactivation or has been 
silenced (block)237,238.  
In summary, the current preliminary study showed that intact proviruses are 
selectively eliminated in the early suppressed children vs late suppressed 
children which explains why the decay rates of the total HIV-1 DNA were 
different between the two groups post ART initiation. This could help elucidate 
an appropriate time to administer remission strategies in addition to ART to help 
eradicate the replication-competent reservoir. However, more research is 
needed to truly understand the decay dynamics of the reservoir in perinatal HIV-
1 infections to begin working towards a functional cure/remission.  
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The figures below are representative of the individual plots after the analysis of 
the IPDA results of the PHACS-AMP cohort participants eligible for this study. 
 
 
Supplementary Figure 1: Individual plots for participants whose total HIV-1 
DNA copies/million PBMCs were in flux over time on ART. 
The figures here represent the participants whose Total HIV-1 DNA copies/million 
PBMCs were in flux over time on ART as a result of flux in intact and defective HIV-
1 DNA copies/million PBMCs. The intact HIV-1 DNA copies/million PBMCs are 
shown in red, the 3’ deleted/hypermutated and 5’ deleted copies/million PBMCS 
are shown in black and purple respectively. The total HIV-1 DNA copies/ million 
PBMCs are shown in blue and the 2LTR copies/million PBMCs are shown in green. 
The open symbols indicate samples in which HIV-1 DNA was not detected by the 
assay. These samples were set to their respective limit of detection values (shown 
in gold), which vary with the number of cells analyzed. 
 






Supplementary Figure 2: Individual plots for participants whose total HIV-1 
DNA declined over time on ART. 
The figures here represent the participants that whose total HIV-1 DNA declined 
over time. The intact HIV-1 DNA copies/million PBMCs are shown in red, the 3’ 
deleted/hypermutated and 5’ deleted copies/million PBMCs are shown in black and 
purple respectively. The total HIV-1 DNA copies/ million PBMCs are shown in blue 
and the 2LTR copies/million PBMCs are shown in green. The open symbols 
indicate samples in which HIV-1 DNA was not detected by the assay. These 
samples were set to their respective limit of detection values (shown in gold), which 
vary with the number of cells analyzed. 
 






Supplementary Figure 3: Individual plots for participants showing stable total 
HIV-1 DNA copies/million PBMCs over time on ART. 
The figures here represent the participants whose Total HIV-1 DNA copies/million 
PBMCs were stable over time. The different species of HIV-1 DNA were in a state 
of flux even though the total HIV-1 DNA was stable. The intact HIV-1 DNA 
copies/million PBMCs are shown in red, the 3’ deleted and 5’ deleted copies/million 
PBMCs are shown in black and purple respectively. The total HIV-1 DNA copies/ 
million PBMCs are shown in blue and the 2LTR copies/million PBMCs are shown 
in green. The open symbols indicate samples in which HIV-1 DNA was not detected 
by the assay. These samples were set to their respective limit of detection values 
(shown in gold), which vary with the number of cells analyzed. 
 






Supplementary Figure 4: Individual plots for participants with only one time 
point. 
The figures here represent the participants that only had one time point eligible for 
this study. The intact HIV-1 DNA copies/million PBMCs are shown in red, the 3’ 
deleted and 5’ deleted copies/million PBMCs are shown in black and purple 
respectively. The total HIV-1 DNA copies/ million PBMCs are shown in blue and 
the 2LTR copies/million PBMCs are shown in green. The open symbols indicate 
samples in which HIV-1 DNA was not detected by the assay. These samples were 
set to their respective limit of detection values (shown in gold), which vary with the 
number of cells analyzed. 








Supplementary Figure 5: Individual plots of participants that need further 
testing. 
The figures here represent the participants whose samples require further testing. 
The intact HIV-1 DNA copies/million PBMCs are shown in red, the 3’ deleted and 
5’ deleted copies/million PBMCs are shown in black and purple respectively. The 
total HIV-1 DNA copies/ million PBMCs are shown in blue and the 2LTR 
copies/million PBMCs are shown in green. The open symbols indicate samples in 
which HIV-1 DNA was not detected by the assay. These samples were set to their 
respective limit of detection values (shown in gold), which vary with the number of 
cells analyzed. 
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• The role of the Vice president (VP) of 
the Social and Cultural Affairs 
Committee is: To organise events 
which celebrate the cultural diversity in 
the school as well as social and 
networking events targeting the entire 
Student Association.  
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